fluorouracil has been researched along with Angiogenesis, Pathologic in 195 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Induction cisplatin and gemcitabine chemotherapy is a standard treatment for locally advanced nasopharyngeal carcinoma (NPC)." | 9.34 | Integration of Antiangiogenic Therapy with Cisplatin and Gemcitabine Chemotherapy in Patients with Nasopharyngeal Carcinoma. ( Chan, GHJ; Chong, SM; Chong, WQ; Goh, BC; Goh, RM; Ho, FCH; Huang, Y; Jeyasekharan, AD; Kong, LR; Kumarakulasinghe, NB; Lau, JA; Lee, SC; Lim, CM; Lim, YC; Loh, KS; Loh, WS; Sinha, AK; Soo, RA; Soon, YY; Sundar, R; Tai, BC; Tan, CS; Tay, JK; Wang, L; Wong, AL; Yadav, K, 2020) |
| "A novel combination of capecitabine, oxaliplatin, and bevacizumab was evaluated in colorectal cancer patients enrolled in a phase II clinical trial." | 9.17 | Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab. ( Amara, A; Bulusu, A; Honeycutt, W; Hurwitz, HI; Liu, Y; Nixon, AB; Pang, H; Starr, MD; Wong, NS, 2013) |
| "The phase III CONFIRM clinical trials demonstrated that metastatic colorectal cancer patients with elevated serum lactate dehydrogenase (LDH) had improved outcome when the vascular endothelial growth factor receptor (VEGFR) inhibitor PTK/ZK (Vatalanib) was added to FOLFOX4 chemotherapy." | 9.17 | Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib). ( Azuma, M; Danenberg, KD; Danenberg, PV; Folprecht, G; Ladner, RD; Lebwohl, D; Lenz, HJ; Meinhardt, G; Sherrod, A; Shi, MM; Trarbach, T; Wilson, PM; Yang, D; Zhang, W, 2013) |
| "To evaluate the combination of bevacizumab with infusional 5-fluorouracil (5-FU), leucovorin (LV) and irinotecan (FOLFIRI) in patients with advanced colorectal cancer (CRC) pretreated with combination regimens including irinotecan and oxaliplatin." | 9.12 | Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. ( Kim, HJ; Kim, SH; Kwon, HC; Lee, S; Oh, SY, 2007) |
| "5-Fluorouracil (5-FU) is one of the most effective drugs for the treatment of colorectal cancer (CRC)." | 7.96 | Enalapril overcomes chemoresistance and potentiates antitumor efficacy of 5-FU in colorectal cancer by suppressing proliferation, angiogenesis, and NF-κB/STAT3-regulated proteins. ( Cai, J; Li, W; Liu, Y; Ma, L; Xu, Y; Yang, Y; Zhang, Y, 2020) |
| "5-Fluorouracil-based therapy remains the main approach in colorectal cancer, even though there are still some drawbacks, such as chemoresistance." | 7.96 | Liposomal simvastatin sensitizes C26 murine colon carcinoma to the antitumor effects of liposomal 5-fluorouracil in vivo. ( Achim, M; Banciu, M; Casian, T; Dragos, N; Drotar, DM; Licarete, E; Luput, L; Muntean, D; Patras, L; Porfire, A; Rauca, VF; Sesarman, A; Stejerean, I; Toma, VA; Tomuta, I; Vlase, L, 2020) |
| " Furthermore and interestingly, in contrast to the currently used antiangiogenic agents, DA also prevented 5-fluorouracil (5FU) induced neutropenia in HT29 colon cancer bearing mice." | 7.81 | Dopamine is a safe antiangiogenic drug which can also prevent 5-fluorouracil induced neutropenia. ( Basu, S; Chakroborty, D; Dasgupta, PS; Sarkar, C, 2015) |
| "We report a case of long-term survival of a patient with hepatocellular carcinoma( HCC) with portal vein tumor thrombus (PVTT) treated with fluorouracil arterial infusion and interferon therapy (FAIT)." | 7.79 | [Long-term survival of a patient with hepatocellular carcinoma with portal vein tumor thrombus treated with interferon-α and 5-fluorouracil combination therapy]. ( Akita, H; Doki, Y; Eguchi, H; Hama, N; Kawamoto, K; Kobayashi, S; Mori, M; Nagano, H; Tomimaru, Y; Tsuda, Y; Umeshita, K; Wada, H, 2013) |
| " In this study, patient-derived tumor tissue (PDTT) xenograft models of primary colon carcinoma and lymphatic and hepatic metastases were established for assessment of the antitumor activity of FP3 in combination with capecitabine." | 7.78 | Antitumor effects of FP3 in combination with capecitabine on PDTT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases. ( Cao, F; Han, N; He, K; Jin, K; Lan, H; Li, G; Teng, L; Xie, B; Xu, Z, 2012) |
| " The aim of the present study was to analyse the possible predictive value of miRNA-126 in relation to first line capecitabine and oxaliplatin (XELOX) in patients with metastatic colorectal cancer (mCRC)." | 7.78 | The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer. ( Hansen, TF; Jakobsen, A; Lindebjerg, J; Sørensen, FB, 2012) |
| "We report a case of successful treatment by interferon-α (IFN) and 5-fluorouracil (5-FU) combination therapy and transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT)." | 7.77 | [A case of successful treatment by interferon-α and 5-fluorouracil combination therapy (FAIT) and transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus]. ( Doki, Y; Eguchi, H; Kawamoto, K; Kishimoto, T; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Tanemura, M; Umeshita, K; Wada, H, 2011) |
| "Inhibition of TP may be beneficial in decreasing angiogenesis-dependent growth and migration of cholangiocarcinoma but may diminish the response to 5-fluorouracil chemotherapy." | 7.76 | Effects of thymidine phosphorylase on tumor aggressiveness and 5-fluorouracil sensitivity in cholangiocarcinoma. ( Jearanaikoon, P; Limpaiboon, T; Miwa, M; Pairojkul, C; Sripa, B; Tantimavanich, S; Thanasai, J, 2010) |
| " The aims of the present study were to compare, in vitro and in vivo, the antiangiogenic and antitumor activities of metronomic irinotecan (CPT-11), oxaliplatin (L-OHP) and 5-fluorouracil (5-FU) in colorectal cancer and to investigate the metronomic combination of these drugs." | 7.75 | Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. ( Alì, G; Allegrini, G; Bocci, G; Canu, B; Danesi, R; Del Tacca, M; Di Desidero, T; Emmenegger, U; Falcone, A; Fioravanti, A; Fontanini, G; Orlandi, P, 2009) |
| " The aim of our current study was to examine the combined effect of ACE-I and 5-fluorouracil (5-FU), which is widely used for hepatogastrointestinal tumors, on hepatocellular carcinoma (HCC) growth and hepatocarcinogenesis." | 7.74 | Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities. ( Akahane, T; Asada, K; Fukui, H; Ikenaka, Y; Kaji, K; Kitade, M; Namisaki, T; Noguchi, R; Tsujimoto, T; Uemura, M; Yamazaki, M; Yanase, K; Yoshii, J; Yoshiji, H, 2007) |
| "The levels of both VEGF and PDGF-BB were measured in three time points, in the serum of 32 rectal carcinoma patients receiving daily reduced-dose/continuous capecitabine in combination with preoperative pelvic irradiation." | 7.74 | Daily low-dose/continuous capecitabine combined with neo-adjuvant irradiation reduces VEGF and PDGF-BB levels in rectal carcinoma patients. ( Be'ery, E; Fenig, E; Koren, C; Lavi, I; Loven, D; Shaked, Y; Sulkes, A; Yerushalmi, R, 2008) |
| "We recently reported that interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) combination therapy in advanced hepatocellular carcinoma (HCC) achieved excellent clinical results." | 7.74 | Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins. ( Arai, I; Damdinsuren, B; Doki, Y; Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Noda, T; Ota, H; Sakon, M; Takeda, Y; Umeshita, K; Wada, H; Yamamoto, H, 2007) |
| "We investigated the antiproliferative effects of interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) in combination on a hepatocellular carcinoma (HCC) cell line." | 7.73 | Antiproliferative effects of 5-fluorouracil and interferon-alpha in combination on a hepatocellular carcinoma cell line in vitro and in vivo. ( Kojiro, M; Kojiro, S; Momosaki, S; Nishida, N; Ogasawara, S; Takemoto, Y; Yano, H, 2006) |
| "Ibuprofen significantly inhibited cell proliferation in mouse (MC-26) and human (HT-29) colorectal cancer cell lines." | 7.73 | Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. ( Albert, A; Chang, AJ; Liu, TC; Sangha, S; Wolfe, MM; Yao, M; Zhou, W, 2005) |
| " We undertook a retrospective study comparing the incidences of hand-foot syndrome in 67 patients with metastatic colorectal cancer who took capecitabine (Xeloda) with or without celecoxib." | 7.71 | Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. ( Ayers, GD; Lin, E; Morris, JS, 2002) |
| "5-Fluorouracil (5-FU) was injected subconjunctivally after glaucoma filtering surgery in a pilot study of eyes with poor surgical prognoses." | 7.67 | 5-fluorouracil and glaucoma filtering surgery. II. A pilot study. ( Anderson, DR; Gressel, MG; Heuer, DK; Hodapp, E; Palmberg, PF; Parrish, RK, 1984) |
| "5-FU-mediated augmented lung metastasis was associated with increases in intrapulmonary neutrophil numbers and expression of neutrophilic chemokines, Cxcl1 and Cxcl2 in tumor cells, with few effects on intrapulmonary T-cell or macrophage numbers." | 5.48 | Involvement of Prokineticin 2-expressing Neutrophil Infiltration in 5-Fluorouracil-induced Aggravation of Breast Cancer Metastasis to Lung. ( Baba, T; Matsugo, S; Mukaida, N; Muranaka, H; Sasaki, S; Takahashi, C; Tanabe, Y, 2018) |
| "Lenalidomide is an oral drug with immune-modulatory and anti-angiogenic activity against selected hematologic malignancies but as yet little is known regarding its effectiveness for solid tumors." | 5.43 | Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity. ( Aglietta, M; Bertotti, A; Bussolino, F; Gammaitoni, L; Giraudo, E; Giraudo, L; Grignani, G; Leone, F; Leuci, V; Luraghi, P; Maione, F; Mesiano, G; Migliardi, G; Rotolo, R; Sangiolo, D; Sassi, F; Todorovic, M; Trusolino, L, 2016) |
| "Induction cisplatin and gemcitabine chemotherapy is a standard treatment for locally advanced nasopharyngeal carcinoma (NPC)." | 5.34 | Integration of Antiangiogenic Therapy with Cisplatin and Gemcitabine Chemotherapy in Patients with Nasopharyngeal Carcinoma. ( Chan, GHJ; Chong, SM; Chong, WQ; Goh, BC; Goh, RM; Ho, FCH; Huang, Y; Jeyasekharan, AD; Kong, LR; Kumarakulasinghe, NB; Lau, JA; Lee, SC; Lim, CM; Lim, YC; Loh, KS; Loh, WS; Sinha, AK; Soo, RA; Soon, YY; Sundar, R; Tai, BC; Tan, CS; Tay, JK; Wang, L; Wong, AL; Yadav, K, 2020) |
| "A novel combination of capecitabine, oxaliplatin, and bevacizumab was evaluated in colorectal cancer patients enrolled in a phase II clinical trial." | 5.17 | Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab. ( Amara, A; Bulusu, A; Honeycutt, W; Hurwitz, HI; Liu, Y; Nixon, AB; Pang, H; Starr, MD; Wong, NS, 2013) |
| "The phase III CONFIRM clinical trials demonstrated that metastatic colorectal cancer patients with elevated serum lactate dehydrogenase (LDH) had improved outcome when the vascular endothelial growth factor receptor (VEGFR) inhibitor PTK/ZK (Vatalanib) was added to FOLFOX4 chemotherapy." | 5.17 | Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib). ( Azuma, M; Danenberg, KD; Danenberg, PV; Folprecht, G; Ladner, RD; Lebwohl, D; Lenz, HJ; Meinhardt, G; Sherrod, A; Shi, MM; Trarbach, T; Wilson, PM; Yang, D; Zhang, W, 2013) |
| "To evaluate the combination of bevacizumab with infusional 5-fluorouracil (5-FU), leucovorin (LV) and irinotecan (FOLFIRI) in patients with advanced colorectal cancer (CRC) pretreated with combination regimens including irinotecan and oxaliplatin." | 5.12 | Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. ( Kim, HJ; Kim, SH; Kwon, HC; Lee, S; Oh, SY, 2007) |
| "A phase II trial was initiated to analyze the activity of continuously administered pioglitazone and rofecoxib combined with low-dose chemotherapy (capecitabine or temozolomide) in patients with high-grade gliomas (glioblastoma or anaplastic glioma)." | 5.12 | Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study. ( Baumgart, U; Bogdahn, U; Hau, P; Hirschmann, B; Kunz-Schughart, L; Muhleisen, H; Reichle, A; Ruemmele, P; Steinbrecher, A; Weimann, E, 2007) |
| "5-Fluorouracil- and leucovorin-based chemotherapy regimens are the backbone of colorectal cancer treatment." | 4.98 | Thymidine phosphorylase: the unforeseen driver in colorectal cancer treatment? ( Bironzo, P; Di Maio, M; Scagliotti, GV; Tampellini, M, 2018) |
| "In patients with stage III colorectal cancer (CRC) who have undergone potentially curative resection, adjuvant treatment with 6 months' of 5-fluorouracil (5-FU) plus folinic acid (FA) is generally accepted as standard treatment and leads to a 5% to 10% improvement in absolute survival when compared with a no-chemotherapy control." | 4.82 | Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors. ( Cascinu, S; Georgoulias, V; Kerr, D; Labianca, R; Maughan, T; Ychou, M, 2003) |
| "Recent trials have established the IFL combination (fluorouracil [5-FU], leucovorin, and irinotecan [CPT-11, Camptosar]) as a new standard first-line therapy for patients with metastatic colorectal cancer." | 4.81 | Targeting vascular endothelial growth factor in colorectal cancer. ( Berlin, JD, 2002) |
| "5-Fluorouracil-based therapy remains the main approach in colorectal cancer, even though there are still some drawbacks, such as chemoresistance." | 3.96 | Liposomal simvastatin sensitizes C26 murine colon carcinoma to the antitumor effects of liposomal 5-fluorouracil in vivo. ( Achim, M; Banciu, M; Casian, T; Dragos, N; Drotar, DM; Licarete, E; Luput, L; Muntean, D; Patras, L; Porfire, A; Rauca, VF; Sesarman, A; Stejerean, I; Toma, VA; Tomuta, I; Vlase, L, 2020) |
| "5-Fluorouracil (5-FU) is one of the most effective drugs for the treatment of colorectal cancer (CRC)." | 3.96 | Enalapril overcomes chemoresistance and potentiates antitumor efficacy of 5-FU in colorectal cancer by suppressing proliferation, angiogenesis, and NF-κB/STAT3-regulated proteins. ( Cai, J; Li, W; Liu, Y; Ma, L; Xu, Y; Yang, Y; Zhang, Y, 2020) |
| "Metronomic chemotherapy using the 5-FU prodrug uracil-tegafur (UFT) and cyclophosphamide (CTX) was previously shown to only modestly delay primary tumor growth, but nevertheless markedly suppressed the development of micro-metastasis in an orthotopic breast cancer xenograft model, using the metastatic variant of the MDA-MB-231 cell line, 231/LM2-4." | 3.91 | Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion. ( Cruz-Muñoz, W; Hileeto, D; Kerbel, RS; Man, S; Muñoz, R; Viloria-Petit, A; Wood, GA; Xu, P, 2019) |
| " Furthermore and interestingly, in contrast to the currently used antiangiogenic agents, DA also prevented 5-fluorouracil (5FU) induced neutropenia in HT29 colon cancer bearing mice." | 3.81 | Dopamine is a safe antiangiogenic drug which can also prevent 5-fluorouracil induced neutropenia. ( Basu, S; Chakroborty, D; Dasgupta, PS; Sarkar, C, 2015) |
| "We report a case of long-term survival of a patient with hepatocellular carcinoma( HCC) with portal vein tumor thrombus (PVTT) treated with fluorouracil arterial infusion and interferon therapy (FAIT)." | 3.79 | [Long-term survival of a patient with hepatocellular carcinoma with portal vein tumor thrombus treated with interferon-α and 5-fluorouracil combination therapy]. ( Akita, H; Doki, Y; Eguchi, H; Hama, N; Kawamoto, K; Kobayashi, S; Mori, M; Nagano, H; Tomimaru, Y; Tsuda, Y; Umeshita, K; Wada, H, 2013) |
| " The aim of the present study was to analyse the possible predictive value of miRNA-126 in relation to first line capecitabine and oxaliplatin (XELOX) in patients with metastatic colorectal cancer (mCRC)." | 3.78 | The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer. ( Hansen, TF; Jakobsen, A; Lindebjerg, J; Sørensen, FB, 2012) |
| " In this study, patient-derived tumor tissue (PDTT) xenograft models of primary colon carcinoma and lymphatic and hepatic metastases were established for assessment of the antitumor activity of FP3 in combination with capecitabine." | 3.78 | Antitumor effects of FP3 in combination with capecitabine on PDTT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases. ( Cao, F; Han, N; He, K; Jin, K; Lan, H; Li, G; Teng, L; Xie, B; Xu, Z, 2012) |
| "We report a case of successful treatment by interferon-α (IFN) and 5-fluorouracil (5-FU) combination therapy and transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT)." | 3.77 | [A case of successful treatment by interferon-α and 5-fluorouracil combination therapy (FAIT) and transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus]. ( Doki, Y; Eguchi, H; Kawamoto, K; Kishimoto, T; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Tanemura, M; Umeshita, K; Wada, H, 2011) |
| "Inhibition of TP may be beneficial in decreasing angiogenesis-dependent growth and migration of cholangiocarcinoma but may diminish the response to 5-fluorouracil chemotherapy." | 3.76 | Effects of thymidine phosphorylase on tumor aggressiveness and 5-fluorouracil sensitivity in cholangiocarcinoma. ( Jearanaikoon, P; Limpaiboon, T; Miwa, M; Pairojkul, C; Sripa, B; Tantimavanich, S; Thanasai, J, 2010) |
| " The aims of the present study were to compare, in vitro and in vivo, the antiangiogenic and antitumor activities of metronomic irinotecan (CPT-11), oxaliplatin (L-OHP) and 5-fluorouracil (5-FU) in colorectal cancer and to investigate the metronomic combination of these drugs." | 3.75 | Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. ( Alì, G; Allegrini, G; Bocci, G; Canu, B; Danesi, R; Del Tacca, M; Di Desidero, T; Emmenegger, U; Falcone, A; Fioravanti, A; Fontanini, G; Orlandi, P, 2009) |
| "We recently reported that interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) combination therapy in advanced hepatocellular carcinoma (HCC) achieved excellent clinical results." | 3.74 | Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins. ( Arai, I; Damdinsuren, B; Doki, Y; Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Noda, T; Ota, H; Sakon, M; Takeda, Y; Umeshita, K; Wada, H; Yamamoto, H, 2007) |
| "The levels of both VEGF and PDGF-BB were measured in three time points, in the serum of 32 rectal carcinoma patients receiving daily reduced-dose/continuous capecitabine in combination with preoperative pelvic irradiation." | 3.74 | Daily low-dose/continuous capecitabine combined with neo-adjuvant irradiation reduces VEGF and PDGF-BB levels in rectal carcinoma patients. ( Be'ery, E; Fenig, E; Koren, C; Lavi, I; Loven, D; Shaked, Y; Sulkes, A; Yerushalmi, R, 2008) |
| " The aim of our current study was to examine the combined effect of ACE-I and 5-fluorouracil (5-FU), which is widely used for hepatogastrointestinal tumors, on hepatocellular carcinoma (HCC) growth and hepatocarcinogenesis." | 3.74 | Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities. ( Akahane, T; Asada, K; Fukui, H; Ikenaka, Y; Kaji, K; Kitade, M; Namisaki, T; Noguchi, R; Tsujimoto, T; Uemura, M; Yamazaki, M; Yanase, K; Yoshii, J; Yoshiji, H, 2007) |
| " We used a fibrin-thrombin clot-based angiogenesis model to evaluate the angiogenic response of human breast cancer to various cytotoxic agents commonly used in its treatment." | 3.74 | A novel assay to assess the effectiveness of antiangiogenic drugs in human breast cancer. ( Anthony, CT; Lyons, JM; Thomson, JL; Woltering, EA, 2008) |
| " For this purpose, we assessed the impact of cellular supernatants of the primary adenocarcinoma cell line CCL228, its lymph node metastasis CCL227, and four subclones resistant to different levels of 5-fluorouracil on the growth of microvascular and macrovascular endothelial cells." | 3.74 | Angiogenic effect of naive and 5-fluorouracil resistant colon carcinoma on endothelial cells in vitro. ( Mader, RM; Schönau, KK; Steger, GG, 2007) |
| "Ibuprofen significantly inhibited cell proliferation in mouse (MC-26) and human (HT-29) colorectal cancer cell lines." | 3.73 | Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. ( Albert, A; Chang, AJ; Liu, TC; Sangha, S; Wolfe, MM; Yao, M; Zhou, W, 2005) |
| "We investigated the antiproliferative effects of interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) in combination on a hepatocellular carcinoma (HCC) cell line." | 3.73 | Antiproliferative effects of 5-fluorouracil and interferon-alpha in combination on a hepatocellular carcinoma cell line in vitro and in vivo. ( Kojiro, M; Kojiro, S; Momosaki, S; Nishida, N; Ogasawara, S; Takemoto, Y; Yano, H, 2006) |
| " injection with 5-fluorouracil/leukovorin (5-FU/LV) for 5 days (20 mg and 10 mg/kg body weight respectively)." | 3.73 | Comparison between triple therapy with octreotide, galanin and serotonin vs. irinotecan or oxaliplatin in combination with 5-fluorouracil/leukovorin in human colon cancer. ( El-Salhy, M; Hilding, L; Royson, H; Tjomsland, V, 2005) |
| "We examined the mechanisms underlying the enhancement of radiosensitivity and chemosensitivity to gamma-irradiation (IR) and 5-Fluorouracil (5-FU) in human oral carcinoma cells (B88) in which NF-kappaB activity was constitutively suppressed." | 3.72 | Enhanced radiosensitization and chemosensitization in NF-kappaB-suppressed human oral cancer cells via the inhibition of gamma-irradiation- and 5-FU-induced production of IL-6 and IL-8. ( Ashida, Y; Azuma, M; Harada, K; Kawaguchi, S; Motegi, K; Sato, M; Takashima, R; Tamatani, T, 2004) |
| " We undertook a retrospective study comparing the incidences of hand-foot syndrome in 67 patients with metastatic colorectal cancer who took capecitabine (Xeloda) with or without celecoxib." | 3.71 | Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. ( Ayers, GD; Lin, E; Morris, JS, 2002) |
| " We examined TP expression using immunohistochemistry (654-1 Mab) in 182 invasive breast carcinomas (67 N0 and 115 N1/2; median follow-up 78 months [range, 3-177]; 51 patients treated with adjuvant systemic cyclophosphamide, methotrexate and 5-fluorouracil [CMF] chemotherapy and 82 with tamoxifen)." | 3.71 | Prognostic value of thymidine phosphorylase expression in breast carcinoma. ( Barbareschi, M; Caffo, O; Dalla Palma, P; Galligioni, E; Kakudo, K; Mauri, F; Mori, I; Muscarà, M; Nakamura, M; Nakamura, Y; Sakurai, T; Yang, Q; Yoshimura, G, 2002) |
| " Using a murine dorsal air sac (DAS) assay, we have previously shown that UFT and its metabolites, gamma-hydroxybutyric acid (GHB) and 5-fluorouracil (5-FU), inhibited the angiogenesis induced by murine renal cell carcinoma." | 3.71 | gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. ( Aoyagi, K; Basaki, Y; Chikahisa, L; Hashimoto, A; Miyadera, K; Okabe, S; Wierzba, K; Yamada, Y; Yonekura, K, 2001) |
| "The antimetabolite 5-fluorouracil (5-FU) was used as adjunctive treatment in glaucomatous eyes with poor prognoses undergoing filtering surgery." | 3.67 | Adjusting the dose of 5-fluorouracil after filtration surgery to minimize side effects. ( Weinreb, RN, 1987) |
| "5-Fluorouracil (5-FU) was injected subconjunctivally after glaucoma filtering surgery in a pilot study of eyes with poor surgical prognoses." | 3.67 | 5-fluorouracil and glaucoma filtering surgery. II. A pilot study. ( Anderson, DR; Gressel, MG; Heuer, DK; Hodapp, E; Palmberg, PF; Parrish, RK, 1984) |
| "In many cancers TP is expressed at high levels and promotes thymidine catabolism, ultimately generating 2-deoxyribose (2dDR) that can support multiple procancer processes, including glycation of proteins, alternative metabolism, extracellular matrix remodeling, and angiogenesis." | 2.82 | Multifunctional role of thymidine phosphorylase in cancer. ( Reigan, P; Warfield, BM, 2022) |
| "Advanced pancreatic cancer, in addition to its high mortality, is characterized by one of the highest rates of venous thromboembolic events (VTE) as compared to other types of cancer." | 2.73 | Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). ( Bramlage, P; Dörken, B; Hilbig, A; Kauschat-Brüning, D; Oettle, H; Opitz, B; Pelzer, U; Riess, H; Scholten, T; Stieler, J, 2008) |
| "Continuous dosing of the combination of capecitabine and celecoxib was well tolerated, produced antiangiogenic effects, and has antitumor activity." | 2.73 | Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients--results of a phase II study. ( Arends, J; Drevs, J; Frost, A; Häring, B; Hennig, J; Medinger, M; Mross, K; Steinbild, S; Strecker, R; Unger, C, 2007) |
| "Colorectal cancer is the second leading cause of cancer-related death worldwide." | 2.72 | Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept. ( Aranda Aguilar, E; Élez Fernández, E; Fernández Montes, A; García-Alfonso, P; González Astorga, B; González Flores, E; López Muñoz, AM; Salud Salvia, A; Salvà Ballabrera, F; Vera García, R, 2021) |
| "Among these are the following." | 2.66 | Prospective computerized simulation of breast cancer: comparison of computer predictions with nine sets of biological and clinical data. ( Headley, DL; Retsky, MW; Swartzendruber, DE; Wardwell, RH, 1987) |
| "Metastatic breast cancer (MBC) is an incurable disease." | 2.49 | [Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer]. ( Belbaraka, R; Elomrani, A; Ismaili, N; Khouchani, M; Tahri, A, 2013) |
| "Colorectal cancers have been the first cancers to benefit from an efficient anti-angiogenic treatment, represented by bevacizumab, which has been approved for first-line metastatic treatment in combination with reference chemotherapies and which is under study in the adjuvant setting." | 2.44 | [Angiogenesis targeting in gastro-intestinal cancers]. ( Meric, JB, 2007) |
| " Moreover, though HE staining and organ index measurement, 2'-FL was validated to alleviate toxic effects on liver and kidney tissue when combining with 5-Fu." | 1.72 | 2'-Fucosyllactose Suppresses Angiogenesis and Alleviates Toxic Effects of 5-Fu in a HCT116 Colon Tumor-Bearing Model. ( Li, H; Wang, B; Wang, Y, 2022) |
| "TBG inhibits SW620 colon cancer growth, induces apoptosis SMAC-XIAP-Caspases signaling, induces cellular senescence through CDKN1a/CDKN2a-RB-E2F signaling, inhibits angiogenesis by down-regulation of HIF-1α and VEGF, and enhances the effects of 5-Fu." | 1.72 | Tenglong Buzhong granules inhibits the growth of SW620 human colon cancer. ( Bing, HU; Hongmei, AN; Jialu, Z; Jinfang, C; Lei, C; Miao, LI; Shuangshuang, W; Xiao, P, 2022) |
| "In this study we subjected the gastric cancer cell line AGS to chronic exposure of 5-fluorouracil, cisplatin or paclitaxel, thus selecting cell subpopulations showing resistance to the different drugs." | 1.62 | Enhanced Vasculogenic Capacity Induced by 5-Fluorouracil Chemoresistance in a Gastric Cancer Cell Line. ( Andreucci, E; Barbato, G; Biagioni, A; Cianchi, F; Coratti, F; Giovannelli, L; Magnelli, L; Papucci, L; Peri, S; Schiavone, N; Staderini, F; Versienti, G, 2021) |
| "ARID1A was expressed at low levels in breast cancer cells." | 1.56 | Role of ARID1A in epithelial‑mesenchymal transition in breast cancer and its effect on cell sensitivity to 5‑FU. ( Gao, S; Gao, X; Jiang, T; Liu, P; Shi, X; Wang, T; Zhou, K; Zuo, X, 2020) |
| " WGA-EF-NP exhibited superior anti-tumor activity and pro-apoptotic efficacy compared to the drugs and nanoparticles without WGA decoration owing to better bioavailability and longer circulation time in vivo." | 1.51 | Enhanced anti-colon cancer efficacy of 5-fluorouracil by epigallocatechin-3- gallate co-loaded in wheat germ agglutinin-conjugated nanoparticles. ( Chen, J; Chen, Z; Di, L; Hu, L; Huang, J; Li, J; Qiao, H; Wang, H; Wang, R; Yang, M, 2019) |
| "5-FU-mediated augmented lung metastasis was associated with increases in intrapulmonary neutrophil numbers and expression of neutrophilic chemokines, Cxcl1 and Cxcl2 in tumor cells, with few effects on intrapulmonary T-cell or macrophage numbers." | 1.48 | Involvement of Prokineticin 2-expressing Neutrophil Infiltration in 5-Fluorouracil-induced Aggravation of Breast Cancer Metastasis to Lung. ( Baba, T; Matsugo, S; Mukaida, N; Muranaka, H; Sasaki, S; Takahashi, C; Tanabe, Y, 2018) |
| "Esophageal squamous cell carcinoma (ESCC) is the second common cancer in Henan province and is well-known for aggressiveness and dismal prognosis." | 1.46 | All-trans retinoic acid suppresses the angiopoietin-Tie2 pathway and inhibits angiogenesis and metastasis in esophageal squamous cell carcinoma. ( Cui, H; Li, D; Li, N; Li, S; Lian, J; Lu, T; Lu, Y; Sang, L; Wang, Y; Yu, JJ; Zhang, L; Zheng, X, 2017) |
| "Three colon cancer cell lines (RKO, LoVo, and SW480) were used as in vitro models." | 1.43 | Ursolic acid sensitized colon cancer cells to chemotherapy under hypoxia by inhibiting MDR1 through HIF-1α. ( Huang, JJ; Shan, JZ; Xuan, YY; Zhang, Q, 2016) |
| "Lenalidomide is an oral drug with immune-modulatory and anti-angiogenic activity against selected hematologic malignancies but as yet little is known regarding its effectiveness for solid tumors." | 1.43 | Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity. ( Aglietta, M; Bertotti, A; Bussolino, F; Gammaitoni, L; Giraudo, E; Giraudo, L; Grignani, G; Leone, F; Leuci, V; Luraghi, P; Maione, F; Mesiano, G; Migliardi, G; Rotolo, R; Sangiolo, D; Sassi, F; Todorovic, M; Trusolino, L, 2016) |
| "5-Fluorouracil (5-FU) has been used as a chemotherapeutic drug for various types of cancer, although the development of resistance remains a major limitation for its use in clinical settings." | 1.42 | Anti-angiogenic effects of resveratrol in combination with 5-fluorouracil on B16 murine melanoma cells. ( Kim, YM; Koo, BS; Lee, SH; Park, SY, 2015) |
| "Luteolin was found to up-regulate the expression of ICAM-1 in H22 hepatoma tissue, of which the middle-dose group had the most obvious effect, showing a significant difference (P < 0." | 1.42 | Effect of luteolin on gene expression in mouse H22 hepatoma cells. ( Bao, LD; Gan, HM; Guo, HP; Niu, JX; Ren, JJ, 2015) |
| "Whether simvastatin can sensitize the gastric cancer to the antitumor effects of capecitabine in vitro and in vivo was investigated." | 1.40 | Simvastatin sensitizes human gastric cancer xenograft in nude mice to capecitabine by suppressing nuclear factor-kappa B-regulated gene products. ( Ahn, KS; Chen, L; Kumar, AP; Li, F; Manu, KA; Sethi, G; Shanmugam, MK; Siveen, KS, 2014) |
| "The formation of liver metastases in colorectal cancer patients is the primary cause of patient death." | 1.40 | Suppression of colorectal cancer liver metastasis by apolipoprotein(a) kringle V in a nude mouse model through the induction of apoptosis in tumor-associated endothelial cells. ( Ahn, JH; Hong, SW; Kim, JS; Kim, SJ; Lee, HJ; Yu, HK, 2014) |
| "CRF has been detected in breast cancer tissues; however, the biological effects reported in the literature are sparse and variable." | 1.40 | Corticotropin-releasing factor reduces tumor volume, halts further growth, and enhances the effect of chemotherapy in 4T1 mammary carcinoma in mice. ( Reed, RK; Stuhr, LE; Wei, ET, 2014) |
| "Aspirin is a salicylate drug that is widely used, and recently it has been shown to influence the development of various types of cancers." | 1.39 | Impact of acetylsalicylic acid on tumor angiogenesis and lymphangiogenesis through inhibition of VEGF signaling in a murine sarcoma model. ( Jia, Q; Wang, Z; Wu, L; Zhang, W; Zhang, X; Zhang, Y, 2013) |
| "Carbon monoxide was a mediator of HMOX1 effects on proliferation, migration, and miR-378 expression." | 1.39 | Interplay between heme oxygenase-1 and miR-378 affects non-small cell lung carcinoma growth, vascularization, and metastasis. ( Boczkowski, J; Ciesla, M; Collet, G; Dulak, J; Gil, T; Golda, S; Guichard, A; Jozkowicz, A; Kieda, C; Kozakowska, M; Kuzdzal, J; Loboda, A; Muchova, L; Skrzypek, K; Tertil, M; Vitek, L; Was, H; Weglarczyk, K, 2013) |
| "Whether γ-tocotrienol can sensitize gastric cancer to capecitabine in vitro and in a xenograft mouse model was investigated." | 1.38 | First evidence that γ-tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capecitabine in a xenograft mouse model through the modulation of NF-κB pathway. ( Fong, CW; Kumar, AP; Li, F; Manu, KA; Ramachandran, L; Sethi, G; Shanmugam, MK; Tan, P, 2012) |
| "Angiogenesis inhibitors combined with chemotherapeutic drugs have significant efficacy in the treatment of a variety of cancers." | 1.38 | Angiogenesis inhibition and cell cycle arrest induced by treatment with Pseudolarix acid B alone or combined with 5-fluorouracil. ( Chu, M; Cui, J; Fu, H; Guo, W; Liu, J; Ran, F; Xu, B, 2012) |
| " Here, it was tried to evaluate the antiangiogenic effect of IFN-alpha in combination with chemotherapy." | 1.35 | Interferon-alpha in combination with chemotherapy has potent antiangiogenic properties in an orthotopic mouse model for pancreatic adenocarcinoma. ( Büchler, MW; Hackert, T; Jäger, D; Märten, A; Ryschich, E; Schmidt, J; Tibensky, I; Zhu, Y, 2008) |
| "The growth and metastasis of human colon cancer implanted in nude mice were significantly inhibited in Endostatin, SU6668, Endostatin plus SU6668, and Endostatin plus SU6668 and 5-FU, and the effect of Endostatin plus SU6668 and 5-FU was the most obviously." | 1.35 | [Effect of Endostatin and SU6668 combined with 5-FU on human colon cancer xenograft in nude mice]. ( Chu, ZH; Luo, XJ; Zeng, QL; Zhou, K, 2008) |
| "Capecitabine is a novel fluoropyrimidine carbamate, which has a broader spectrum of antitumor activity than other fluoropyrimidines, such as 5-FU, DFUR, or UFT; it has proved effective over a wide dose range." | 1.35 | Antiangiogenic effect of capecitabine combined with ginsenoside Rg3 on breast cancer in mice. ( Kang, X; Wang, J; Yang, B; Yang, F; Zhang, Q, 2008) |
| "Prostate cancer is the most common malignancy in men." | 1.34 | Bevacizumab plus 5-fluorouracil induce growth suppression in the CWR-22 and CWR-22R prostate cancer xenografts. ( Hung, H, 2007) |
| "The growth and metastasis of human gastric cancer implanted in SCID mice were significantly inhibited in SU6668 group and combined group, especially in combined group." | 1.33 | [Effect of angiogenesis inhibitor SU6668 on the growth and metastasis of gastric cancer in SCID mice]. ( Jiang, XT; Tao, HQ; Zou, SC, 2006) |
| "Human colon cancer cells were injected subcutaneous in nude mice." | 1.33 | Anti-tumour effects of triple therapy with octreotide, galanin and serotonin in comparison with those of 5-fluorouracil/leukovorin on human colon cancer. ( El-Salhy, M; Tjomsland, V, 2005) |
| "Advanced colorectal cancer specimens (n=97) were prepared for immunohistochemical staining using monoclonal antibodies against TP, p53, vascular endothelial growth factor (VEGF), factor VIII, CD68 and thymidylate synthase (TS)." | 1.33 | Importance of thymidine phosphorylase expression in tumor stroma as a prognostic factor in patients with advanced colorectal carcinoma. ( Koike, M; Matsumoto, H; Mori, T; Shimizu, S; Takahashi, K; Takizawa, T; Toi, M; Yamaguchi, T; Yasuno, M, 2005) |
| "The failure to treat gastric cancer is often due to the recurrence or dismal metastasis of cancer and the poor response to traditional chemotherapeutic or radiotherapeutic regimens." | 1.33 | [Effect of vascular endothelial growth factor antibody Avastin on angiogenesis of human gastric cancer growing orthotopically in nude mice]. ( Wang, B; Wang, N; Wang, YJ, 2006) |
| "Human colon cancer cells were implanted s." | 1.32 | Comparison between triple therapy with octreotide, galanin and serotonin, 5-fluorouracil/leucovorin, and sequential treatment with both, on human colon cancer. ( El-Salhy, M, 2004) |
| " Thus, by using a dosing schedule of cyclophosphamide that provided more sustained apoptosis of endothelial cells within the vascular bed of a tumor, we show that a chemotherapeutic agent can more effectively control tumor growth in mice, regardless of whether the tumor cells are drug resistant." | 1.31 | Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. ( Browder, T; Butterfield, CE; Folkman, J; Kräling, BM; Marshall, B; O'Reilly, MS; Shi, B, 2000) |
| "We found that the hazard function of metastasis in time presented two peaks of incidence at 20 and 60 months, respectively." | 1.31 | Angiogenesis sustains tumor dormancy in patients with breast cancer treated with adjuvant chemotherapy. ( Biganzoli, E; Bonoldi, E; Boracchi, P; Fanelli, M; Gasparini, G; Morabito, A, 2001) |
| "5 mg/kg), or cisplatin (4 mg/kg, by one shot) to TNP (120-140 mg/kg) with a 6-7 fractionated dosing schedule reduced s." | 1.29 | Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470) and cytotoxic agents in mice. ( Kakinuma, H; Kato, T; Matsuda, Y; Sato, K, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (4.10) | 18.7374 |
| 1990's | 11 (5.64) | 18.2507 |
| 2000's | 83 (42.56) | 29.6817 |
| 2010's | 79 (40.51) | 24.3611 |
| 2020's | 14 (7.18) | 2.80 |
| Authors | Studies |
|---|---|
| Vijay Avin, BR | 1 |
| Thirusangu, P | 2 |
| Lakshmi Ranganatha, V | 1 |
| Firdouse, A | 1 |
| Prabhakar, BT | 2 |
| Khanum, SA | 2 |
| Mohammed, YHE | 1 |
| Malojirao, VH | 1 |
| Al-Ghorbani, M | 1 |
| Shehatta, NH | 1 |
| Okda, TM | 1 |
| Omran, GA | 1 |
| Abd-Alhaseeb, MM | 1 |
| Warfield, BM | 1 |
| Reigan, P | 1 |
| Li, X | 5 |
| Wang, X | 2 |
| Liu, N | 2 |
| Wang, Q | 2 |
| Hu, J | 1 |
| Miao, LI | 1 |
| Jialu, Z | 1 |
| Shuangshuang, W | 1 |
| Lei, C | 1 |
| Xiao, P | 1 |
| Jinfang, C | 1 |
| Hongmei, AN | 1 |
| Bing, HU | 1 |
| Li, H | 1 |
| Wang, B | 2 |
| Wang, Y | 2 |
| Muñoz, R | 1 |
| Hileeto, D | 1 |
| Cruz-Muñoz, W | 1 |
| Wood, GA | 1 |
| Xu, P | 1 |
| Man, S | 1 |
| Viloria-Petit, A | 1 |
| Kerbel, RS | 1 |
| Nohria, A | 1 |
| Luput, L | 2 |
| Sesarman, A | 2 |
| Porfire, A | 2 |
| Achim, M | 2 |
| Muntean, D | 2 |
| Casian, T | 1 |
| Patras, L | 2 |
| Rauca, VF | 1 |
| Drotar, DM | 2 |
| Stejerean, I | 1 |
| Tomuta, I | 2 |
| Vlase, L | 2 |
| Dragos, N | 1 |
| Toma, VA | 1 |
| Licarete, E | 2 |
| Banciu, M | 2 |
| Yang, Y | 1 |
| Ma, L | 1 |
| Xu, Y | 2 |
| Liu, Y | 2 |
| Li, W | 4 |
| Cai, J | 1 |
| Zhang, Y | 5 |
| Chong, WQ | 1 |
| Lim, CM | 1 |
| Sinha, AK | 1 |
| Tan, CS | 1 |
| Chan, GHJ | 1 |
| Huang, Y | 1 |
| Kumarakulasinghe, NB | 1 |
| Sundar, R | 1 |
| Jeyasekharan, AD | 1 |
| Loh, WS | 1 |
| Tay, JK | 1 |
| Yadav, K | 1 |
| Wang, L | 3 |
| Wong, AL | 1 |
| Kong, LR | 1 |
| Soo, RA | 1 |
| Lau, JA | 1 |
| Soon, YY | 1 |
| Goh, RM | 1 |
| Ho, FCH | 1 |
| Chong, SM | 1 |
| Lee, SC | 1 |
| Loh, KS | 1 |
| Tai, BC | 1 |
| Lim, YC | 1 |
| Goh, BC | 1 |
| He, Y | 1 |
| Qin, HY | 1 |
| Gu, DY | 1 |
| Lu, X | 1 |
| Hu, JX | 1 |
| Ye, WL | 1 |
| He, GB | 1 |
| Wang, T | 2 |
| Gao, X | 1 |
| Zhou, K | 3 |
| Jiang, T | 1 |
| Gao, S | 1 |
| Liu, P | 1 |
| Zuo, X | 1 |
| Shi, X | 1 |
| Zheng, X | 2 |
| Liu, J | 4 |
| Tian, R | 1 |
| Shang, K | 1 |
| Dong, X | 1 |
| Cao, B | 1 |
| Cheng, L | 2 |
| Liu, W | 2 |
| Zhong, C | 1 |
| Ni, P | 2 |
| Ni, S | 2 |
| Zhang, Q | 3 |
| Zhang, J | 4 |
| Xu, M | 1 |
| Yao, X | 2 |
| Cen, X | 1 |
| Wang, G | 2 |
| Jiang, C | 2 |
| Zhou, F | 2 |
| González Astorga, B | 1 |
| Salvà Ballabrera, F | 1 |
| Aranda Aguilar, E | 1 |
| Élez Fernández, E | 1 |
| García-Alfonso, P | 2 |
| González Flores, E | 1 |
| Vera García, R | 1 |
| Fernández Montes, A | 1 |
| López Muñoz, AM | 1 |
| Salud Salvia, A | 1 |
| Peri, S | 1 |
| Biagioni, A | 1 |
| Versienti, G | 1 |
| Andreucci, E | 1 |
| Staderini, F | 1 |
| Barbato, G | 1 |
| Giovannelli, L | 1 |
| Coratti, F | 1 |
| Schiavone, N | 1 |
| Cianchi, F | 1 |
| Papucci, L | 1 |
| Magnelli, L | 1 |
| Li, N | 1 |
| Lu, Y | 1 |
| Li, D | 1 |
| Lian, J | 1 |
| Li, S | 1 |
| Cui, H | 1 |
| Zhang, L | 3 |
| Sang, L | 1 |
| Yu, JJ | 1 |
| Lu, T | 1 |
| Oumrani, S | 1 |
| Guillaumot, MA | 1 |
| Brieau, B | 1 |
| Oudjit, A | 1 |
| Léandri, C | 1 |
| Brezault, C | 1 |
| Chaussade, S | 1 |
| Coriat, R | 1 |
| Sylvester, B | 1 |
| Rusu, AD | 1 |
| Nagy, AL | 1 |
| Catoi, C | 1 |
| Lu, L | 2 |
| Li, ZJ | 2 |
| Li, LF | 2 |
| Shen, J | 2 |
| Li, MX | 1 |
| Xiao, ZG | 1 |
| Wang, JH | 1 |
| Cho, CH | 2 |
| Tang, YC | 1 |
| Zhou, J | 1 |
| Zhi, Q | 1 |
| Wu, MY | 1 |
| Gong, FR | 1 |
| Shen, M | 1 |
| Liu, L | 1 |
| Tao, M | 1 |
| Shen, B | 1 |
| Gu, DM | 1 |
| Yu, J | 1 |
| Xu, MD | 1 |
| Gao, Y | 1 |
| Tabernero, J | 2 |
| Hozak, RR | 2 |
| Yoshino, T | 2 |
| Cohn, AL | 2 |
| Obermannova, R | 2 |
| Bodoky, G | 2 |
| Garcia-Carbonero, R | 2 |
| Ciuleanu, TE | 1 |
| Portnoy, DC | 2 |
| Prausová, J | 2 |
| Muro, K | 2 |
| Siegel, RW | 1 |
| Konrad, RJ | 1 |
| Ouyang, H | 1 |
| Melemed, SA | 1 |
| Ferry, D | 1 |
| Nasroulah, F | 2 |
| Van Cutsem, E | 2 |
| Sasaki, S | 1 |
| Baba, T | 2 |
| Muranaka, H | 1 |
| Tanabe, Y | 1 |
| Takahashi, C | 1 |
| Matsugo, S | 1 |
| Mukaida, N | 1 |
| Zichi, C | 1 |
| Tampellini, M | 3 |
| Tucci, M | 1 |
| Sonetto, C | 1 |
| Baratelli, C | 2 |
| Brizzi, MP | 3 |
| Scagliotti, GV | 3 |
| Bironzo, P | 1 |
| Di Maio, M | 2 |
| Chang, J | 1 |
| Bhasin, SS | 1 |
| Bielenberg, DR | 1 |
| Sukhatme, VP | 1 |
| Bhasin, M | 1 |
| Huang, S | 1 |
| Kieran, MW | 1 |
| Panigrahy, D | 1 |
| Sturrock, M | 1 |
| Miller, IS | 1 |
| Kang, G | 1 |
| Hannis Arba'ie, N | 1 |
| O'Farrell, AC | 1 |
| Barat, A | 1 |
| Marston, G | 1 |
| Coletta, PL | 1 |
| Byrne, AT | 1 |
| Prehn, JH | 1 |
| Chen, Q | 1 |
| Li, Q | 1 |
| Zeynali-Moghaddam, S | 1 |
| Mohammadian, M | 1 |
| Kheradmand, F | 1 |
| Fathi-Azarbayjani, A | 1 |
| Rasmi, Y | 1 |
| Esna-Ashari, O | 1 |
| Malekinejad, H | 1 |
| Ciuleanu, T | 1 |
| Yamazaki, K | 1 |
| Lonardi, S | 2 |
| Kim, TW | 1 |
| Yamaguchi, K | 1 |
| Grothey, A | 1 |
| O'Connor, J | 1 |
| Taieb, J | 1 |
| Wijayawardana, SR | 1 |
| Panaro, F | 1 |
| Kellil, T | 1 |
| Vendrell, J | 1 |
| Sega, V | 1 |
| Souche, R | 1 |
| Piardi, T | 1 |
| Leon, P | 1 |
| Cassinotto, C | 1 |
| Assenat, E | 1 |
| Rosso, E | 1 |
| Navarro, F | 1 |
| Wang, R | 1 |
| Huang, J | 1 |
| Chen, J | 1 |
| Yang, M | 1 |
| Wang, H | 1 |
| Qiao, H | 1 |
| Chen, Z | 2 |
| Hu, L | 1 |
| Di, L | 1 |
| Li, J | 1 |
| Zhang, X | 1 |
| Wang, Z | 4 |
| Jia, Q | 2 |
| Wu, L | 2 |
| Zhang, W | 8 |
| Skrzypek, K | 1 |
| Tertil, M | 1 |
| Golda, S | 1 |
| Ciesla, M | 1 |
| Weglarczyk, K | 1 |
| Collet, G | 1 |
| Guichard, A | 1 |
| Kozakowska, M | 1 |
| Boczkowski, J | 1 |
| Was, H | 1 |
| Gil, T | 1 |
| Kuzdzal, J | 1 |
| Muchova, L | 1 |
| Vitek, L | 1 |
| Loboda, A | 1 |
| Jozkowicz, A | 1 |
| Kieda, C | 1 |
| Dulak, J | 1 |
| Robinson, SM | 1 |
| Mann, J | 1 |
| Vasilaki, A | 1 |
| Mathers, J | 1 |
| Burt, AD | 1 |
| Oakley, F | 1 |
| White, SA | 1 |
| Mann, DA | 1 |
| Starr, MD | 1 |
| Bulusu, A | 1 |
| Pang, H | 1 |
| Wong, NS | 1 |
| Honeycutt, W | 1 |
| Amara, A | 1 |
| Hurwitz, HI | 1 |
| Nixon, AB | 1 |
| Ismaili, N | 1 |
| Belbaraka, R | 1 |
| Elomrani, A | 1 |
| Khouchani, M | 1 |
| Tahri, A | 1 |
| Tsuji, W | 1 |
| Ishiguro, H | 1 |
| Tanaka, S | 1 |
| Takeuchi, M | 1 |
| Ueno, T | 1 |
| Toi, M | 2 |
| Hansen, TF | 3 |
| Nielsen, BS | 1 |
| Jakobsen, A | 3 |
| Sørensen, FB | 3 |
| Loupakis, F | 3 |
| Cremolini, C | 2 |
| Yang, D | 5 |
| Salvatore, L | 2 |
| Wakatsuki, T | 1 |
| Bohanes, P | 2 |
| Schirripa, M | 2 |
| Benhaim, L | 2 |
| Antoniotti, C | 1 |
| Aprile, G | 1 |
| Graziano, F | 1 |
| Ruzzo, A | 1 |
| Lucchesi, S | 1 |
| Ronzoni, M | 1 |
| De Vita, F | 1 |
| Tonini, G | 1 |
| Falcone, A | 3 |
| Lenz, HJ | 5 |
| Christensen, Rd | 1 |
| Andersen, RF | 1 |
| Johnsson, A | 1 |
| Stuhr, LE | 2 |
| Wei, ET | 1 |
| Reed, RK | 2 |
| Alishekevitz, D | 1 |
| Bril, R | 1 |
| Loven, D | 2 |
| Miller, V | 1 |
| Voloshin, T | 1 |
| Gingis-Velistki, S | 1 |
| Fremder, E | 1 |
| Scherer, SJ | 1 |
| Shaked, Y | 2 |
| Manu, KA | 2 |
| Shanmugam, MK | 2 |
| Li, F | 2 |
| Chen, L | 1 |
| Siveen, KS | 1 |
| Ahn, KS | 1 |
| Kumar, AP | 2 |
| Sethi, G | 2 |
| Zhang, B | 2 |
| Chen, X | 2 |
| Bae, S | 1 |
| Singh, K | 1 |
| Washington, MK | 1 |
| Datta, PK | 1 |
| Tsuda, Y | 1 |
| Kobayashi, S | 2 |
| Tomimaru, Y | 1 |
| Akita, H | 1 |
| Hama, N | 1 |
| Wada, H | 3 |
| Kawamoto, K | 2 |
| Eguchi, H | 2 |
| Umeshita, K | 3 |
| Doki, Y | 3 |
| Mori, M | 2 |
| Nagano, H | 3 |
| Sui, W | 1 |
| Peguero, J | 1 |
| Khanfar, A | 1 |
| Mannem, S | 1 |
| Willis, M | 1 |
| Markowtiz, A | 1 |
| Ahn, JH | 1 |
| Yu, HK | 1 |
| Lee, HJ | 1 |
| Hong, SW | 1 |
| Kim, SJ | 1 |
| Kim, JS | 1 |
| Shi, H | 1 |
| Jiang, J | 1 |
| Ji, J | 1 |
| Shi, M | 1 |
| Cai, Q | 1 |
| Yu, Y | 1 |
| Liu, B | 1 |
| Zhu, Z | 1 |
| Chan, MS | 1 |
| Chen, SF | 1 |
| Felizola, SJ | 1 |
| Nemoto, N | 1 |
| Tamaki, K | 1 |
| Ishida, T | 1 |
| Chow, LW | 1 |
| Ohuchi, N | 1 |
| Sasano, H | 1 |
| Hayashi, H | 1 |
| Arao, T | 1 |
| Matsumoto, K | 2 |
| Kimura, H | 1 |
| Togashi, Y | 1 |
| Hirashima, Y | 1 |
| Horita, Y | 1 |
| Iwasa, S | 1 |
| Okita, NT | 1 |
| Honma, Y | 1 |
| Takashima, A | 1 |
| Kato, K | 1 |
| Hamaguchi, T | 1 |
| Shimada, Y | 1 |
| Nakagawa, K | 1 |
| Nishio, K | 1 |
| Yamada, Y | 4 |
| Bruchard, M | 1 |
| Ghiringhelli, F | 1 |
| Ramcharan, KS | 1 |
| Lip, GY | 1 |
| Stonelake, PS | 1 |
| Blann, AD | 1 |
| Sarkar, C | 1 |
| Chakroborty, D | 1 |
| Dasgupta, PS | 1 |
| Basu, S | 1 |
| Maione, F | 2 |
| Oliaro-Bosso, S | 1 |
| Meda, C | 1 |
| Di Nicolantonio, F | 1 |
| Bussolino, F | 2 |
| Balliano, G | 1 |
| Viola, F | 1 |
| Giraudo, E | 2 |
| Lee, SH | 1 |
| Koo, BS | 1 |
| Park, SY | 2 |
| Kim, YM | 1 |
| Song, D | 1 |
| Meng, T | 1 |
| Xu, W | 2 |
| Hou, T | 1 |
| Lin, Z | 1 |
| Yin, H | 1 |
| Li, B | 2 |
| Zhou, L | 1 |
| Han, S | 1 |
| Fan, T | 1 |
| Miao, W | 1 |
| Liu, M | 1 |
| Luo, J | 1 |
| Zhou, W | 2 |
| Li, Z | 1 |
| Xiao, J | 1 |
| Wu, WK | 1 |
| Chan, RL | 1 |
| Yu, L | 1 |
| Liu, YW | 1 |
| Ren, SX | 1 |
| Chan, KM | 1 |
| Jary, M | 1 |
| Borg, C | 1 |
| Bouché, O | 1 |
| Kim, S | 1 |
| André, T | 1 |
| Bennouna, J | 1 |
| Kotlarz, A | 1 |
| Przybyszewska, M | 1 |
| Swoboda, P | 1 |
| Miłoszewska, J | 1 |
| Grygorowicz, MA | 1 |
| Kutner, A | 1 |
| Markowicz, S | 1 |
| Niu, JX | 1 |
| Guo, HP | 1 |
| Gan, HM | 1 |
| Bao, LD | 1 |
| Ren, JJ | 1 |
| Matsusaka, S | 1 |
| Hanna, DL | 1 |
| Cao, S | 1 |
| Ning, Y | 2 |
| Sunakawa, Y | 1 |
| Okazaki, S | 1 |
| Berger, MD | 1 |
| Miyamato, Y | 1 |
| Parekh, A | 1 |
| Stintzing, S | 1 |
| Kim, N | 1 |
| Cho, SB | 1 |
| Park, YL | 1 |
| Myung, E | 1 |
| Kim, SH | 2 |
| Yu, HM | 1 |
| Son, YA | 1 |
| Myung, DS | 1 |
| Lee, WS | 1 |
| Joo, YE | 1 |
| Leuci, V | 1 |
| Rotolo, R | 1 |
| Sassi, F | 1 |
| Migliardi, G | 1 |
| Todorovic, M | 1 |
| Gammaitoni, L | 1 |
| Mesiano, G | 1 |
| Giraudo, L | 1 |
| Luraghi, P | 1 |
| Leone, F | 1 |
| Grignani, G | 1 |
| Aglietta, M | 1 |
| Trusolino, L | 1 |
| Bertotti, A | 1 |
| Sangiolo, D | 1 |
| Zhao, X | 1 |
| Du, B | 1 |
| Liu, S | 1 |
| Yang, XY | 1 |
| Ding, H | 1 |
| Yang, W | 1 |
| Pan, F | 1 |
| Wu, X | 1 |
| Qin, L | 1 |
| Pan, Y | 1 |
| Gned, D | 1 |
| Ottone, A | 1 |
| Alabiso, I | 1 |
| Bertaggia, C | 1 |
| Veltri, A | 1 |
| Shan, JZ | 1 |
| Xuan, YY | 1 |
| Huang, JJ | 1 |
| He, F | 1 |
| Chen, H | 1 |
| Yang, P | 1 |
| Wu, Q | 1 |
| Zhang, T | 1 |
| Wang, C | 1 |
| Wei, J | 2 |
| Hu, H | 1 |
| Cao, J | 1 |
| Lurje, G | 1 |
| Schultheis, AM | 1 |
| Groshen, S | 1 |
| Hendifar, AE | 1 |
| Husain, H | 1 |
| Gordon, MA | 1 |
| Nagashima, F | 1 |
| Chang, HM | 1 |
| Zeng, QL | 1 |
| Chu, ZH | 1 |
| Luo, XJ | 1 |
| Zhao, HY | 1 |
| Ooyama, A | 1 |
| Yamamoto, M | 1 |
| Ikeda, R | 1 |
| Haraguchi, M | 1 |
| Tabata, S | 1 |
| Furukawa, T | 1 |
| Che, XF | 1 |
| Zhang, S | 1 |
| Oka, T | 1 |
| Fukushima, M | 1 |
| Nakagawa, M | 1 |
| Ono, M | 1 |
| Kuwano, M | 2 |
| Akiyama, S | 1 |
| Lyons, JM | 1 |
| Anthony, CT | 1 |
| Thomson, JL | 1 |
| Woltering, EA | 1 |
| Moriya, F | 1 |
| Ogasawara, S | 2 |
| Basaki, Y | 3 |
| Akiba, J | 1 |
| Kojiro, S | 2 |
| Fukahori, S | 1 |
| Ishizaki, H | 1 |
| Nishida, N | 2 |
| Matsuoka, K | 1 |
| Kojiro, M | 2 |
| Yano, H | 2 |
| Kang, X | 1 |
| Yang, B | 1 |
| Wang, J | 2 |
| Yang, F | 1 |
| Baker, JH | 1 |
| Lam, J | 1 |
| Kyle, AH | 1 |
| Sy, J | 1 |
| Oliver, T | 1 |
| Co, SJ | 1 |
| Dragowska, WH | 1 |
| Ramsay, E | 1 |
| Anantha, M | 1 |
| Ruth, TJ | 1 |
| Adam, MJ | 1 |
| Yung, A | 1 |
| Kozlowski, P | 1 |
| Minchinton, AI | 1 |
| Ng, SS | 1 |
| Bally, MB | 1 |
| Yapp, DT | 1 |
| Riess, H | 1 |
| Pelzer, U | 1 |
| Hilbig, A | 1 |
| Stieler, J | 1 |
| Opitz, B | 1 |
| Scholten, T | 1 |
| Kauschat-Brüning, D | 1 |
| Bramlage, P | 1 |
| Dörken, B | 1 |
| Oettle, H | 1 |
| Sakamoto, K | 1 |
| Maeda, S | 1 |
| Hikiba, Y | 1 |
| Nakagawa, H | 1 |
| Hayakawa, Y | 1 |
| Shibata, W | 1 |
| Yanai, A | 1 |
| Ogura, K | 1 |
| Omata, M | 1 |
| Finn, RS | 1 |
| Zhu, AX | 2 |
| Obara, N | 1 |
| Ema, M | 1 |
| Horie, M | 1 |
| Naka, A | 1 |
| Takahashi, S | 1 |
| Imagawa, S | 1 |
| Saltz, L | 1 |
| Viale, G | 1 |
| Giobbie-Hurder, A | 1 |
| Gusterson, BA | 1 |
| Maiorano, E | 1 |
| Mastropasqua, MG | 1 |
| Sonzogni, A | 1 |
| Mallon, E | 1 |
| Colleoni, M | 1 |
| Castiglione-Gertsch, M | 1 |
| Regan, MM | 1 |
| Price, KN | 1 |
| Brown, RW | 1 |
| Golouh, R | 1 |
| Crivellari, D | 1 |
| Karlsson, P | 1 |
| Öhlschlegel, C | 1 |
| Gelber, RD | 1 |
| Goldhirsch, A | 1 |
| Coates, AS | 1 |
| Xiong, YQ | 1 |
| Sun, HC | 1 |
| Zhu, XD | 1 |
| Zhuang, PY | 1 |
| Zhang, JB | 1 |
| Wu, WZ | 1 |
| Qin, LX | 1 |
| Tang, ZY | 1 |
| Fioravanti, A | 2 |
| Canu, B | 2 |
| Alì, G | 1 |
| Orlandi, P | 2 |
| Allegrini, G | 1 |
| Di Desidero, T | 2 |
| Emmenegger, U | 1 |
| Fontanini, G | 1 |
| Danesi, R | 2 |
| Del Tacca, M | 1 |
| Bocci, G | 2 |
| Vidaurreta, M | 1 |
| Sánchez-Muñoz, R | 1 |
| Veganzones, S | 1 |
| Rafael, S | 1 |
| Gutiérrez, M | 1 |
| de-la-Orden, V | 1 |
| Fernández, C | 1 |
| Arroyo, M | 1 |
| Cerdán, FJ | 1 |
| Maestro de las Casas, ML | 1 |
| Thanasai, J | 1 |
| Limpaiboon, T | 1 |
| Jearanaikoon, P | 1 |
| Sripa, B | 1 |
| Pairojkul, C | 1 |
| Tantimavanich, S | 1 |
| Miwa, M | 1 |
| Vizio, B | 1 |
| Novarino, A | 1 |
| Giacobino, A | 1 |
| Cristiano, C | 1 |
| Prati, A | 1 |
| Brondino, G | 1 |
| Ciuffreda, L | 1 |
| Bellone, G | 1 |
| Escorcia, FE | 1 |
| Henke, E | 1 |
| McDevitt, MR | 1 |
| Villa, CH | 1 |
| Smith-Jones, P | 1 |
| Blasberg, RG | 1 |
| Benezra, R | 1 |
| Scheinberg, DA | 1 |
| Dubey, PK | 2 |
| Singodia, D | 1 |
| Verma, RK | 1 |
| Vyas, SP | 2 |
| Papageorgis, P | 1 |
| Cheng, K | 1 |
| Ozturk, S | 1 |
| Gong, Y | 1 |
| Lambert, AW | 1 |
| Abdolmaleky, HM | 1 |
| Zhou, JR | 1 |
| Thiagalingam, S | 1 |
| Masi, G | 1 |
| Frumento, P | 1 |
| Di Paolo, A | 1 |
| Gerger, A | 1 |
| El-Khoueiry, A | 1 |
| Singh, H | 1 |
| Winder, T | 1 |
| Labonte, MJ | 1 |
| Wilson, PM | 2 |
| Paez, D | 1 |
| El-Khoueiry, R | 1 |
| Absenger, G | 1 |
| Kishimoto, T | 1 |
| Marubashi, S | 2 |
| Tanemura, M | 1 |
| Yu, DC | 1 |
| Lee, JS | 1 |
| Yoo, JY | 1 |
| Shin, H | 1 |
| Deng, H | 1 |
| Wei, Y | 1 |
| Yun, CO | 1 |
| Zheng, YB | 1 |
| Cao, FY | 1 |
| Liu, KJ | 1 |
| Gan, HF | 1 |
| He, XB | 1 |
| Tong, SL | 1 |
| Ramachandran, L | 1 |
| Fong, CW | 1 |
| Tan, P | 1 |
| Lindebjerg, J | 1 |
| Luan, Y | 1 |
| Jing, F | 1 |
| Zou, M | 1 |
| Jia, Y | 1 |
| Mou, J | 1 |
| Guo, W | 1 |
| Xu, B | 1 |
| Ran, F | 1 |
| Chu, M | 1 |
| Fu, H | 1 |
| Cui, J | 1 |
| Jin, K | 1 |
| Lan, H | 1 |
| Xie, B | 1 |
| He, K | 1 |
| Xu, Z | 1 |
| Li, G | 1 |
| Han, N | 1 |
| Teng, L | 1 |
| Cao, F | 1 |
| Cetin, B | 1 |
| Kaplan, MA | 1 |
| Berk, V | 1 |
| Ozturk, SC | 1 |
| Benekli, M | 1 |
| Isıkdogan, A | 1 |
| Ozkan, M | 1 |
| Coskun, U | 1 |
| Buyukberber, S | 1 |
| Azuma, M | 2 |
| Shi, MM | 1 |
| Danenberg, KD | 1 |
| Lebwohl, D | 1 |
| Sherrod, A | 1 |
| Ladner, RD | 1 |
| Danenberg, PV | 1 |
| Trarbach, T | 1 |
| Folprecht, G | 1 |
| Meinhardt, G | 1 |
| Srivastava, J | 1 |
| Siddiq, A | 1 |
| Emdad, L | 1 |
| Santhekadur, PK | 1 |
| Chen, D | 1 |
| Gredler, R | 1 |
| Shen, XN | 1 |
| Robertson, CL | 1 |
| Dumur, CI | 1 |
| Hylemon, PB | 1 |
| Mukhopadhyay, ND | 1 |
| Bhere, D | 1 |
| Shah, K | 1 |
| Ahmad, R | 1 |
| Giashuddin, S | 1 |
| Stafflinger, J | 1 |
| Subler, MA | 1 |
| Windle, JJ | 1 |
| Fisher, PB | 1 |
| Sarkar, D | 1 |
| Reddy, S | 1 |
| Raffin, M | 1 |
| Kaklamani, V | 1 |
| Zhu, Q | 1 |
| DeFusco, PA | 1 |
| Ricci, A | 1 |
| Cronin, EB | 1 |
| Hegde, PU | 1 |
| Kane, M | 1 |
| Tavakoli, B | 1 |
| Hart, J | 1 |
| Tannenbaum, SH | 1 |
| Berlin, JD | 1 |
| Lin, E | 1 |
| Morris, JS | 1 |
| Ayers, GD | 1 |
| Yi, J | 1 |
| Liao, X | 1 |
| Yang, Z | 1 |
| Akbulut, H | 1 |
| Altuntas, F | 1 |
| Akbulut, KG | 1 |
| Ozturk, G | 1 |
| Cindoruk, M | 1 |
| Unal, E | 1 |
| Icli, F | 1 |
| Cascinu, S | 1 |
| Georgoulias, V | 2 |
| Kerr, D | 1 |
| Maughan, T | 1 |
| Labianca, R | 1 |
| Ychou, M | 1 |
| Tachibana, M | 1 |
| Yoshimura, H | 1 |
| Kinugasa, S | 1 |
| Shibakita, M | 1 |
| Dhar, DK | 1 |
| Ueda, S | 1 |
| Fujii, T | 1 |
| Nagasue, N | 1 |
| Chu, E | 2 |
| Helbig, M | 1 |
| Schlemmer, HP | 1 |
| Lumer, M | 1 |
| Knopp, MV | 1 |
| Dietz, A | 1 |
| Tamatani, T | 1 |
| Ashida, Y | 1 |
| Motegi, K | 1 |
| Takashima, R | 1 |
| Harada, K | 1 |
| Kawaguchi, S | 1 |
| Sato, M | 1 |
| Seeliger, H | 1 |
| Guba, M | 1 |
| Koehl, GE | 1 |
| Doenecke, A | 1 |
| Steinbauer, M | 1 |
| Bruns, CJ | 1 |
| Wagner, C | 1 |
| Frank, E | 1 |
| Jauch, KW | 1 |
| Geissler, EK | 1 |
| Miller, KD | 1 |
| Zhao, JG | 1 |
| Feng, GS | 1 |
| Kong, XQ | 1 |
| Li, MH | 1 |
| Cheng, YS | 1 |
| El-Salhy, M | 3 |
| Blum, S | 1 |
| Unger, M | 1 |
| Jarmy, G | 1 |
| Lamparter, M | 1 |
| Geishauser, A | 1 |
| Vlastos, GA | 1 |
| Chan, G | 1 |
| Fischer, KD | 1 |
| Rattat, D | 1 |
| Debatin, KM | 1 |
| Hatzopoulos, AK | 1 |
| Beltinger, C | 1 |
| Kabbinavar, FF | 1 |
| Ellis, LM | 2 |
| Mishra, V | 1 |
| Jain, S | 1 |
| Mahor, S | 1 |
| Mandai, M | 1 |
| Fujii, S | 1 |
| Yasuno, M | 1 |
| Mori, T | 1 |
| Koike, M | 1 |
| Takahashi, K | 1 |
| Takizawa, T | 1 |
| Shimizu, S | 1 |
| Yamaguchi, T | 1 |
| Matsumoto, H | 1 |
| Yao, M | 1 |
| Sangha, S | 1 |
| Albert, A | 1 |
| Chang, AJ | 1 |
| Liu, TC | 1 |
| Wolfe, MM | 1 |
| Zhang, Z | 1 |
| Zou, W | 1 |
| Gu, J | 1 |
| Dang, Y | 1 |
| Zhao, L | 1 |
| Qian, C | 1 |
| Qian, Q | 1 |
| Liu, X | 1 |
| Kountouras, J | 1 |
| Zavos, C | 1 |
| Chatzopoulos, D | 1 |
| Ravaud, A | 1 |
| Dilhuydy, MS | 1 |
| Tjomsland, V | 2 |
| Hilding, L | 1 |
| Royson, H | 1 |
| Tóvári, J | 1 |
| Gilly, R | 1 |
| Rásó, E | 1 |
| Paku, S | 1 |
| Bereczky, B | 1 |
| Varga, N | 1 |
| Vágó, A | 1 |
| Tímár, J | 1 |
| Eng, C | 1 |
| Abbruzzese, JL | 1 |
| Gradishar, WJ | 1 |
| Willett, CG | 1 |
| Boucher, Y | 1 |
| Duda, DG | 1 |
| di Tomaso, E | 1 |
| Munn, LL | 1 |
| Tong, RT | 1 |
| Kozin, SV | 1 |
| Petit, L | 1 |
| Jain, RK | 1 |
| Chung, DC | 1 |
| Sahani, DV | 1 |
| Kalva, SP | 1 |
| Cohen, KS | 1 |
| Scadden, DT | 1 |
| Fischman, AJ | 1 |
| Clark, JW | 1 |
| Ryan, DP | 1 |
| Blaszkowsky, LS | 1 |
| Shellito, PC | 1 |
| Mino-Kenudson, M | 1 |
| Lauwers, GY | 1 |
| Kinuya, S | 1 |
| Yokoyama, K | 1 |
| Fukuoka, M | 1 |
| Mori, H | 1 |
| Shiba, K | 1 |
| Watanabe, N | 1 |
| Shuke, N | 1 |
| Michigishi, T | 1 |
| Tonami, N | 1 |
| Holen, KD | 1 |
| Rosen, L | 1 |
| Gordon, MS | 1 |
| Wright, JD | 1 |
| Viviano, D | 1 |
| Powell, MA | 1 |
| Gibb, RK | 1 |
| Mutch, DG | 1 |
| Grigsby, PW | 1 |
| Rader, JS | 1 |
| Fan, YZ | 1 |
| Chen, CQ | 1 |
| Zhao, ZM | 1 |
| Sun, W | 1 |
| Momosaki, S | 1 |
| Takemoto, Y | 1 |
| van Laarhoven, HW | 1 |
| Gambarota, G | 1 |
| Lok, J | 1 |
| Lammens, M | 1 |
| Kamm, YL | 1 |
| Wagener, T | 1 |
| Punt, CJ | 1 |
| van der Kogel, AJ | 1 |
| Heerschap, A | 1 |
| Jiang, XT | 1 |
| Tao, HQ | 1 |
| Zou, SC | 1 |
| Wang, N | 1 |
| Wang, YJ | 1 |
| Salnikov, AV | 1 |
| Iversen, VV | 1 |
| Salvesen, G | 1 |
| Rubin, K | 1 |
| Allen, JA | 1 |
| Adlakha, A | 1 |
| Bergethon, PR | 1 |
| Sledge, GW | 1 |
| Rugo, HS | 1 |
| Burstein, HJ | 1 |
| Lee, CH | 1 |
| Wu, CL | 1 |
| Shiau, AL | 1 |
| Yanase, K | 1 |
| Yoshiji, H | 1 |
| Ikenaka, Y | 1 |
| Noguchi, R | 1 |
| Kitade, M | 1 |
| Kaji, K | 1 |
| Yoshii, J | 1 |
| Namisaki, T | 1 |
| Yamazaki, M | 1 |
| Asada, K | 1 |
| Tsujimoto, T | 1 |
| Akahane, T | 1 |
| Uemura, M | 1 |
| Fukui, H | 1 |
| Irie, T | 1 |
| Tsujii, M | 1 |
| Tsuji, S | 1 |
| Yoshio, T | 1 |
| Ishii, S | 1 |
| Shinzaki, S | 1 |
| Egawa, S | 1 |
| Kakiuchi, Y | 1 |
| Nishida, T | 1 |
| Yasumaru, M | 1 |
| Iijima, H | 1 |
| Murata, H | 1 |
| Takehara, T | 1 |
| Kawano, S | 1 |
| Hayashi, N | 1 |
| Schönau, KK | 1 |
| Steger, GG | 1 |
| Mader, RM | 1 |
| Hung, H | 1 |
| Yamamoto, H | 1 |
| Arai, I | 1 |
| Ota, H | 1 |
| Nakamura, M | 2 |
| Damdinsuren, B | 1 |
| Noda, T | 1 |
| Miyamoto, A | 1 |
| Takeda, Y | 1 |
| Dono, K | 1 |
| Nakamori, S | 1 |
| Sakon, M | 1 |
| Monden, M | 1 |
| Ray-Coquard, I | 1 |
| Bachelot, T | 1 |
| Saba, C | 1 |
| Confavreux, C | 1 |
| Brantus, JF | 1 |
| Rustam, F | 1 |
| Ghesquière, H | 1 |
| Sebban, C | 1 |
| Biron, P | 1 |
| Guastalla, JP | 1 |
| Blay, JY | 1 |
| Huang, KH | 1 |
| Liu, JH | 1 |
| Wang, LY | 1 |
| Zhu, ZH | 1 |
| Chen, QK | 1 |
| Min, J | 1 |
| Chen, RF | 1 |
| Be'ery, E | 1 |
| Yerushalmi, R | 1 |
| Koren, C | 1 |
| Sulkes, A | 1 |
| Lavi, I | 1 |
| Fenig, E | 1 |
| Meric, JB | 1 |
| Steinbild, S | 1 |
| Arends, J | 1 |
| Medinger, M | 1 |
| Häring, B | 1 |
| Frost, A | 1 |
| Drevs, J | 1 |
| Unger, C | 1 |
| Strecker, R | 1 |
| Hennig, J | 1 |
| Mross, K | 1 |
| Kwon, HC | 1 |
| Oh, SY | 1 |
| Lee, S | 1 |
| Kim, HJ | 1 |
| Zhu, Y | 1 |
| Tibensky, I | 1 |
| Schmidt, J | 1 |
| Hackert, T | 1 |
| Ryschich, E | 1 |
| Jäger, D | 1 |
| Büchler, MW | 1 |
| Märten, A | 1 |
| Ranieri, G | 1 |
| Roccaro, AM | 1 |
| Vacca, A | 1 |
| Ribatti, D | 1 |
| Hau, P | 1 |
| Kunz-Schughart, L | 1 |
| Bogdahn, U | 1 |
| Baumgart, U | 1 |
| Hirschmann, B | 1 |
| Weimann, E | 1 |
| Muhleisen, H | 1 |
| Ruemmele, P | 1 |
| Steinbrecher, A | 1 |
| Reichle, A | 1 |
| Blumenkranz, MS | 1 |
| Ophir, A | 1 |
| Claflin, AJ | 1 |
| Hajek, A | 1 |
| Heuer, DK | 2 |
| Parrish, RK | 2 |
| Gressel, MG | 2 |
| Hodapp, E | 2 |
| Palmberg, PF | 2 |
| Anderson, DR | 1 |
| Kato, T | 1 |
| Sato, K | 1 |
| Kakinuma, H | 1 |
| Matsuda, Y | 1 |
| Yamaoka, M | 1 |
| Yamamoto, T | 1 |
| Ikeyama, S | 1 |
| Sudo, K | 1 |
| Fujita, T | 1 |
| Horowitz, R | 1 |
| Schwartz, EL | 1 |
| Wadler, S | 1 |
| Griffiths, L | 1 |
| Stratford, IJ | 1 |
| Blumenthal, RD | 1 |
| Sharkey, RM | 1 |
| Kashi, R | 1 |
| Sides, K | 1 |
| Stein, R | 1 |
| Goldenberg, DM | 1 |
| Takei, H | 1 |
| Iino, Y | 1 |
| Horiguchi, J | 1 |
| Maemura, M | 1 |
| Koibuchi, Y | 1 |
| Nagaoka, H | 1 |
| Yokoe, T | 1 |
| Oyama, T | 1 |
| Morishita, Y | 1 |
| Fujieda, S | 1 |
| Sunaga, H | 1 |
| Tsuzuki, H | 1 |
| Tanaka, N | 1 |
| Saito, H | 2 |
| Giatromanolaki, A | 2 |
| Koukourakis, MI | 2 |
| Gatter, KC | 2 |
| Harris, AL | 2 |
| Fountzilas, G | 2 |
| Yonekura, K | 2 |
| Chikahisa, L | 2 |
| Okabe, S | 2 |
| Hashimoto, A | 3 |
| Miyadera, K | 2 |
| Wierzba, K | 2 |
| Murakami, K | 1 |
| Sakukawa, R | 1 |
| Sano, M | 1 |
| Shibata, J | 1 |
| Saiki, I | 1 |
| Tsujitani, S | 1 |
| Oka, S | 1 |
| Kondo, A | 1 |
| Ikeguchi, M | 1 |
| Maeta, M | 1 |
| Kaibara, N | 1 |
| Sivridis, E | 1 |
| Browder, T | 1 |
| Butterfield, CE | 1 |
| Kräling, BM | 1 |
| Shi, B | 1 |
| Marshall, B | 1 |
| O'Reilly, MS | 1 |
| Folkman, J | 1 |
| Nishimura, G | 1 |
| Yanoma, S | 1 |
| Satake, K | 1 |
| Ikeda, Y | 1 |
| Taguchi, T | 1 |
| Nakamura, Y | 2 |
| Hirose, F | 1 |
| Tsukuda, M | 1 |
| Gasparini, G | 1 |
| Biganzoli, E | 1 |
| Bonoldi, E | 1 |
| Morabito, A | 1 |
| Fanelli, M | 1 |
| Boracchi, P | 1 |
| Marchetti, S | 1 |
| Chazal, M | 1 |
| Dubreuil, A | 1 |
| Fischel, JL | 1 |
| Etienne, MC | 1 |
| Milano, G | 1 |
| Hironaka, S | 1 |
| Hasebe, T | 1 |
| Kamijo, T | 1 |
| Ohtsu, A | 1 |
| Boku, N | 1 |
| Yoshida, S | 2 |
| Saitoh, H | 1 |
| Ochiai, A | 1 |
| Yang, Q | 1 |
| Barbareschi, M | 1 |
| Mori, I | 1 |
| Mauri, F | 1 |
| Muscarà, M | 1 |
| Yoshimura, G | 1 |
| Sakurai, T | 1 |
| Caffo, O | 1 |
| Galligioni, E | 1 |
| Dalla Palma, P | 1 |
| Kakudo, K | 1 |
| Guidi, AJ | 1 |
| Berry, DA | 1 |
| Broadwater, G | 1 |
| Helmchen, B | 1 |
| Bleiweiss, IJ | 1 |
| Budman, DR | 1 |
| Henderson, IC | 1 |
| Norton, L | 1 |
| Hayes, DF | 1 |
| Reimer, CL | 1 |
| Agata, N | 1 |
| Tammam, JG | 1 |
| Bamberg, M | 1 |
| Dickerson, WM | 1 |
| Kamphaus, GD | 1 |
| Rook, SL | 1 |
| Milhollen, M | 1 |
| Fram, R | 1 |
| Kalluri, R | 1 |
| Kufe, D | 1 |
| Kharbanda, S | 1 |
| Aoyagi, K | 1 |
| Davies, MM | 1 |
| Burke, D | 1 |
| Carnochan, P | 1 |
| Glover, C | 1 |
| Kaur, S | 1 |
| Allen-Mersh, TG | 1 |
| Bottini, A | 1 |
| Berruti, A | 1 |
| Bersiga, A | 1 |
| Allevi, G | 1 |
| Bolsi, G | 1 |
| Aguggini, S | 1 |
| Brunelli, A | 1 |
| Betri, E | 1 |
| Generali, D | 1 |
| Scaratti, L | 1 |
| Bertoli, G | 1 |
| Alquati, P | 1 |
| Dogliotti, L | 1 |
| Tynninen, O | 1 |
| Sjöström, J | 1 |
| von Boguslawski, K | 1 |
| Bengtsson, NO | 1 |
| Heikkilä, R | 1 |
| Malmström, P | 1 |
| Ostenstad, B | 1 |
| Wist, E | 1 |
| Valvere, V | 1 |
| Saksela, E | 1 |
| Paavonen, T | 1 |
| Blomqvist, C | 1 |
| Tanaka, NG | 1 |
| Sakamoto, N | 1 |
| Tohgo, A | 1 |
| Nishiyama, Y | 1 |
| Ogawa, H | 1 |
| Desjardins, DC | 1 |
| Skuta, GL | 1 |
| Nevárez, JA | 1 |
| Rockwood, EJ | 1 |
| Weinreb, RN | 1 |
| Retsky, MW | 1 |
| Wardwell, RH | 1 |
| Swartzendruber, DE | 1 |
| Headley, DL | 1 |
| Katz, LJ | 1 |
| Spaeth, GL | 1 |
| Chihara, E | 1 |
| Hayashida, T | 1 |
| Yamamoto, A | 1 |
| Torii, H | 1 |
| Nakamura, A | 1 |
| Sawada, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy Wit[NCT01183780] | Phase 3 | 1,072 participants (Actual) | Interventional | 2010-12-02 | Completed | ||
| Phase II Study of Oxaliplatin, Capecitabine and Bevacizumab in the Treatment of Metastatic Colorectal Cancer[NCT00416494] | Phase 2 | 50 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| Avastin and Chemotherapy Followed by Avastin Alone or in Combination With Tarceva for the Treatment of Metastatic Colorectal Cancer.[NCT00598156] | Phase 3 | 249 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Study to Evaluate the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular Carcinoma[NCT01717066] | 480 participants (Actual) | Interventional | 2012-04-30 | Completed | |||
| 3-D Simultaneous Ultrasound and NIR Imaging for Breast Cancer Detection[NCT00908609] | 340 participants (Actual) | Observational | 2007-04-30 | Completed | |||
| Effect of Topical Diclofenac on Clinical Outcome in Breast Cancer Patients Treated With Capecitabine: A Randomized Controlled Trial.[NCT05641246] | Phase 2 | 66 participants (Anticipated) | Interventional | 2022-12-08 | Active, not recruiting | ||
| Retrospective Analysis of Salvage Therapy With Bevacizumab Plus Docetaxel and Cisplatin for Taiwanese Metastatic Breast Cancer[NCT01025349] | Phase 2 | 20 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| AVF3963s Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer[NCT00600210] | Phase 2 | 0 participants (Actual) | Interventional | 2008-01-31 | Withdrawn (stopped due to low patient accrual) | ||
| Preoperative Radiotherapy With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer: CRAB Phase II Study[NCT00842686] | Phase 2 | 60 participants (Anticipated) | Interventional | 2009-01-31 | Active, not recruiting | ||
| Preoperative Induction Chemotherapy in Combination With Bevacizumab Followed by Combined Chemoradiotherapy in Locally Advanced Rectal Cancer With High Risk of Recurrence- Phase II Pilot Study With Preoperative Administration of Capecitabine (Xeloda), Oxal[NCT01434147] | Phase 2 | 25 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallop[NCT02584478] | Phase 3 | 294 participants (Actual) | Interventional | 2015-12-31 | Active, not recruiting | ||
| "Phase III Clinical Trial: Evaluation of the Combination of TRANSKRIP ® Plus Carboplatin and Paclitaxel as First Line Chemotherapy on Survival of Patients With Recurrent - Persistent Cervical Cancer"[NCT02446652] | Phase 3 | 230 participants (Anticipated) | Interventional | 2015-07-31 | Not yet recruiting | ||
| A Phase 2 Clinical Trial:Low -Dose-bevacizumab and Pemetrexed Versus Treatment of Physician's Choice in Metastatic HER2-negative Breast Cancer Patients After Failure of Taxanes and Anthracycline-containing Regimens[NCT02829008] | Phase 2 | 120 participants (Anticipated) | Interventional | 2016-04-30 | Active, not recruiting | ||
| Multicentre Randomized Phase II Study of Neoadjuvant Trastuzumab Plus Docetaxel With and Without Bevacizumab and Trastuzumab Plus Docetaxel Plus Non-pegylated Liposome-encapsulated Doxorubicin (NPLD) With and Without Bevacizumab in HER2-positive Early Bre[NCT01367028] | Phase 2 | 100 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The EORTC QLQ-C30 (v. 3.0) is a self-administered, cancer-specific questionnaire with multidimensional scales assessing 15 domains (5 functional domains, 9 symptoms, and global health status). A linear transformation was applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For the functional domains and global health status scale, higher scores represent a better level of functioning. For symptom scales, higher scores represent a greater degree of symptoms. Maximum improvement is the best post-baseline change. (NCT01183780)
Timeframe: Baseline Up to 171 Weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Ramucirumab + FOLFIRI | 4.0 |
| Placebo + FOLFIRI | 6.6 |
The EQ-5D is a generic, multidimensional, health status instrument. The profile allows participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood using a 3-level scale (no problem, some problems, and major problems). These combinations of attributes were converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm. The possible values for the Index Score ranged from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension). A negative change indicated a worsening of the participant's health status. (NCT01183780)
Timeframe: Baseline and 30-Day Follow-Up (FU) up to 171 Weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Ramucirumab + FOLFIRI | -0.097 |
| Placebo + FOLFIRI | -0.103 |
OS was defined as the time in months from the date of randomization to the date of death from any cause. For participants not known to have died as of the cut-off date, OS was censored at the last known date alive. (NCT01183780)
Timeframe: Randomization to Date of Death from Any Cause Up to 39.36 Months
| Intervention | months (Median) |
|---|---|
| Ramucirumab + FOLFIRI | 13.3 |
| Placebo + FOLFIRI | 11.7 |
The objective response rate is equal to the proportion of participants achieving a best overall response of partial response or complete response (PR + CR). Response was defined using RECIST, v. 1.1 criteria. CR was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm and normalization of tumor marker level of non-target lesions; PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions taking as reference the baseline sum diameter. (NCT01183780)
Timeframe: Randomization until Disease Progression Up to 38.01 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Ramucirumab + FOLFIRI | 13.4 |
| Placebo + FOLFIRI | 12.5 |
PFS was defined as the time from the date of randomization until the date of objectively determined progressive disease (PD) [according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v). 1.1] or death due to any cause, whichever was first. PD is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). Participants who died without a reported prior progression were considered to have progressed on the day of their death. Participants who did not progress or were lost to follow-up were censored at the day of their last radiographic tumor assessment. (NCT01183780)
Timeframe: Randomization to Measured PD or Date of Death from Any Cause Up to 38.01 Months
| Intervention | months (Median) |
|---|---|
| Ramucirumab + FOLFIRI | 5.7 |
| Placebo + FOLFIRI | 4.5 |
(NCT01183780)
Timeframe: Preinfusion and 1 hour postinfusion in Cycles 3, 5, 9, 13, and 17
| Intervention | micrograms/milliliter (ug/mL) (Geometric Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cmin Dose 3 (n=248) | Cmin Dose 5 (n=154) | Cmin Dose 9 (n=27) | Cmin Dose 13 (n=11) | Cmin Dose 17 (n=5) | Cmax Dose 3 (n=88) | Cmax Dose 5 (n=51) | Cmax Dose 9 (n=18) | Cmax Dose 13 (n=12) | Cmax Dose 17 (n=7) | |
| Ramucirumab + FOLFIRI | 46.3 | 65.1 | 77.9 | 75.9 | 72.0 | 221.0 | 243.0 | 262.0 | 307.0 | 253.0 |
Blood samples were tested to determine if a participant reacted to ramucirumab by producing anti-ramucirumab antibodies. Samples were identified as treatment emergent anti-drug antibody (TE ADA) if the post-treatment sample had an increase of at least 4 fold in titer from pre-treatment values. If the pre-treatment value was not detected or was not present, a 1:20 post-treatment titer was required to indicate treatment emergence. The percentage of participants with TE ADA was calculated as: (the number of participants with TE ADA / total number of participants with at least 1 post-treatment immunogenicity sample analyzed)*100. (NCT01183780)
Timeframe: Cycles 1, 3, 5, and 30-Day FU
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Immunogenicity Any Time During Study (n=516, 512) | Immunogenicity Post-Treatment (n=477, 473) | |
| Placebo + FOLFIRI | 5.5 | 3.8 |
| Ramucirumab + FOLFIRI | 5.6 | 3.1 |
"Disease assessment was performed and recorded according to the Response Evaluation Criteria in Solid Tumors (RECIST v.1.0) Guidelines.~Progressive disease is defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions." (NCT00416494)
Timeframe: From time of treatment until documented progression or death from any cause, whichever came first, assesed up to 60 months.
| Intervention | months (Median) |
|---|---|
| Initial Cohort | 10.1 |
| Second Cohort | 10.4 |
Average months of survival of participants after receiving study drug. (NCT00416494)
Timeframe: From time of treatment until death from any cause, assesed up to 60 months.
| Intervention | months (Median) |
|---|---|
| Initial Cohort | 19.6 |
| Second Cohort | 24.8 |
"Restaging scans occurred every 9 weeks from time of study drug initiation until disease progression.~Disease assessment was performed and recorded according to the Response Evaluation Criteria in Solid Tumors (RECIST v.1.0) Guidelines.~The definitions were:~Complete response (CR)- Disappearance of all target lesions Partial response (PD)- At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD Stable disease (SD)- Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started Progressive disease (PD) - At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions" (NCT00416494)
Timeframe: After all subjects were evaluated for restaging which occured every 9 weeks from drug initiation until disease progression, assesed up to 24 months.
| Intervention | percentage of participants with response (Number) |
|---|---|
| Initial Cohort | 63 |
| Second Cohort | 42 |
Number of participants with adverse events (NCT00416494)
Timeframe: After all participants went off study drug regimine.
| Intervention | participants with adverse event (Number) |
|---|---|
| Initial Cohort | 19 |
| Second Cohort | 29 |
"Disease assessment was performed and recorded according to the Response Evaluation Criteria in Solid Tumors (RECIST v.1.0) Guidelines.~Progressive disease is defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions." (NCT00416494)
Timeframe: From time of treatment until documented progression, assesed up to 60 months.
| Intervention | months (Median) |
|---|---|
| Initial Cohort | 10.1 |
| Second Cohort | 10.4 |
23 reviews available for fluorouracil and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Multifunctional role of thymidine phosphorylase in cancer.
Topics: Fluorouracil; Humans; Neoplasms; Neovascularization, Pathologic; Thymidine; Thymidine Phosphorylase | 2022 |
Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept.
Topics: Age Factors; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined | 2021 |
Thymidine phosphorylase: the unforeseen driver in colorectal cancer treatment?
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Hypoxia; Colorectal Neoplasms; Disea | 2018 |
[Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer].
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic | 2013 |
[Impact of chemotherapies on immunosuppression and discovery of new therapeutic targets].
Topics: Animals; Carrier Proteins; CD4-Positive T-Lymphocytes; Deoxycytidine; Epoxy Compounds; Fluorouracil; | 2014 |
[Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers, Tumor; Camptoth | 2015 |
Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2009 |
Targeting vascular endothelial growth factor in colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2002 |
Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasm | 2003 |
Recent translational research: antiangiogenic therapy for breast cancer - where do we stand?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2004 |
Can inhibition of angiogenic pathways increase the efficacy of intravenous 5-fluorouracil-based regimens?
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2004 |
[Peritoneal dissemination of ovarian cancer and tumor angiogenesis].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; | 2004 |
Apoptotic and anti-angiogenic strategies in liver and gastrointestinal malignancies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2005 |
Interferon alpha for the treatment of advanced renal cancer.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Combined Modality T | 2005 |
The treatment of colorectal carcinoma: standard chemotherapy and beyond.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2004 |
Target practice: figuring out which, when, and why to use systemic therapies for metastatic colon cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; DNA; DNA Topoiso | 2006 |
The role of angiogenesis inhibition in the treatment of breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2006 |
[Are antiangiogenic antibodies universal for solid tumor?].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2007 |
[Angiogenesis targeting in gastro-intestinal cancers].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2007 |
Thymidine phosphorylase (platelet-derived endothelial cell growth factor) as a target for capecitabine: from biology to the bedside.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as | 2006 |
Modulation of 5-fluorouracil by interferon: a review of potential cellular targets.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Combined Modality Therapy; Fluorouracil; Humans; Interfe | 1995 |
Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy.
Topics: Antineoplastic Agents; Endothelial Growth Factors; Fluorouracil; Genes; Humans; Neoplasm Proteins; N | 1997 |
Surgical management of the secondary glaucomas: Part I.
Topics: Ciliary Body; Cryosurgery; Filtration; Fluorouracil; Glaucoma; Humans; Laser Therapy; Light Coagulat | 1987 |
23 trials available for fluorouracil and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Integration of Antiangiogenic Therapy with Cisplatin and Gemcitabine Chemotherapy in Patients with Nasopharyngeal Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free | 2020 |
Remodeling the homeostasis of pro- and anti-angiogenic factors by Shenmai injection to normalize tumor vasculature for enhanced cancer chemotherapy.
Topics: Angiogenesis Inhibitors; Angiostatins; Animals; Antineoplastic Combined Chemotherapy Protocols; Colo | 2021 |
Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immun | 2018 |
Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2019 |
Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimeta | 2013 |
Orally administered S-1 suppresses circulating endothelial cell counts in metastatic breast cancer patients.
Topics: 4-Butyrolactone; Administration, Oral; Adult; Aged; Antigens, CD34; Antimetabolites, Antineoplastic; | 2014 |
MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineop | 2013 |
Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined | 2016 |
Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy).
Topics: Adolescent; Adult; Animals; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Cisplati | 2008 |
Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2010 |
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2011 |
[Value of normalization window of tumor vasculature in neoadjuvant chemotherapy for patients with unresectable gastric cancer].
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2012 |
Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2013 |
Postoperative chemotherapy vs chemoradiotherapy for thoracic esophageal cancer: a prospective randomized clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cis | 2003 |
Can inhibition of angiogenic pathways increase the efficacy of intravenous 5-fluorouracil-based regimens?
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2004 |
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2005 |
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2005 |
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2005 |
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2005 |
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2005 |
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2005 |
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2005 |
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2005 |
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2005 |
Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients--results of a phase II study.
Topics: Administration, Oral; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Capec | 2007 |
Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal | 2007 |
Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Capecitabin | 2007 |
Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer and Leukemia Group B correlative science study from protocols 8541/8869.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 2002 |
Changes in microvessel density as assessed by CD34 antibodies after primary chemotherapy in human breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; | 2002 |
Tumour microvessel density as predictor of chemotherapy response in breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free | 2002 |
Prospective computerized simulation of breast cancer: comparison of computer predictions with nine sets of biological and clinical data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Computer | 1987 |
150 other studies available for fluorouracil and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Synthesis and tumor inhibitory activity of novel coumarin analogs targeting angiogenesis and apoptosis.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Benzophenones; Carcinoma, Ehrlic | 2014 |
The Novel 4-Phenyl-2-Phenoxyacetamide Thiazoles modulates the tumor hypoxia leading to the crackdown of neoangiogenesis and evoking the cell death.
Topics: Acetamides; Animals; Antineoplastic Agents; Cell Death; Cell Proliferation; Dose-Response Relationsh | 2018 |
Baicalin; a promising chemopreventive agent, enhances the antitumor effect of 5-FU against breast cancer and inhibits tumor growth and angiogenesis in Ehrlich solid tumor.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Models, Animal; D | 2022 |
Inhibition of Metastatic Hepatocarcinoma by Combined Chemotherapy with Silencing VEGF/VEGFR2 Genes through a GalNAc-Modified Integrated Therapeutic System.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Fluorouracil; Galactosamine; Liver Neoplasms; | 2022 |
Tenglong Buzhong granules inhibits the growth of SW620 human colon cancer.
Topics: Animals; Cell Line, Tumor; Colonic Neoplasms; Cyclin-Dependent Kinases; Cyclins; Fluorouracil; Human | 2022 |
2'-Fucosyllactose Suppresses Angiogenesis and Alleviates Toxic Effects of 5-Fu in a HCT116 Colon Tumor-Bearing Model.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Fluorouracil; HCT116 Ce | 2022 |
Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cycloph | 2019 |
The clinical conundrum of managing 5-fluorouracil-induced vasospasm in colorectal carcinoma.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Male; Middle Aged; Neop | 2019 |
Liposomal simvastatin sensitizes C26 murine colon carcinoma to the antitumor effects of liposomal 5-fluorouracil in vivo.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Carcinoma; Cell Line, Tumor; Cell Proliferation; Col | 2020 |
Enalapril overcomes chemoresistance and potentiates antitumor efficacy of 5-FU in colorectal cancer by suppressing proliferation, angiogenesis, and NF-κB/STAT3-regulated proteins.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Movement; Cell Proliferation; Color | 2020 |
Inhibitory effect of 5-FU loaded ultrasound microbubbles on tumor growth and angiogenesis.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screeni | 2020 |
Role of ARID1A in epithelial‑mesenchymal transition in breast cancer and its effect on cell sensitivity to 5‑FU.
Topics: Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Survival; DNA-Binding | 2020 |
Angiogenesis is promoted by exosomal DPP4 derived from 5-fluorouracil-resistant colon cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Case-Control Studies; Cell P | 2021 |
Enhanced Vasculogenic Capacity Induced by 5-Fluorouracil Chemoresistance in a Gastric Cancer Cell Line.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Endothelial Cells; Fl | 2021 |
All-trans retinoic acid suppresses the angiopoietin-Tie2 pathway and inhibits angiogenesis and metastasis in esophageal squamous cell carcinoma.
Topics: Angiopoietin-1; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Mov | 2017 |
Tumour growth increased following antiangiogenic interruption: the challenge of tumour evaluation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; F | 2017 |
Liposomal prednisolone phosphate potentiates the antitumor activity of liposomal 5-fluorouracil in C26 murine colon carcinoma in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Ce | 2017 |
A novel vascular-targeting peptide for gastric cancer delivers low-dose TNFα to normalize the blood vessels and improve the anti-cancer efficiency of 5-fluorouracil.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Disease Models, A | 2017 |
Ginsenoside Rg3 targets cancer stem cells and tumor angiogenesis to inhibit colorectal cancer progression in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Co | 2018 |
Involvement of Prokineticin 2-expressing Neutrophil Infiltration in 5-Fluorouracil-induced Aggravation of Breast Cancer Metastasis to Lung.
Topics: Animals; Breast Neoplasms; Cell Proliferation; Chemokine CXCL1; Chemokine CXCL2; Cyclophosphamide; D | 2018 |
FOLFOX activity in a rare case of metastatic colonic adenocarcinoma of the tongue: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Colorectal Neoplasms; Fatal Outcom | 2018 |
Chemotherapy-generated cell debris stimulates colon carcinoma tumor growth via osteopontin.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Colonic Neoplasms; Fluorour | 2019 |
Anti-angiogenic drug scheduling optimisation with application to colorectal cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Prolifera | 2018 |
Bevacizumab-enhanced antitumor effect of 5-fluorouracil via upregulation of thymidine phosphorylase through vascular endothelial growth factor A/vascular endothelial growth factor receptor 2-specificity protein 1 pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Line, Tumor; Colonic Neop | 2018 |
A molecular basis for the synergy between 17‑allylamino‑17‑demethoxy geldanamycin with Capecitabine and Irinotecan in human colorectal cancer cells through VEFG and MMP-9 gene expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Camptothecin; Capecitabine; Colonic N | 2019 |
Microvascular invasion is a major prognostic factor after pancreatico-duodenectomy for adenocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Ad | 2019 |
Enhanced anti-colon cancer efficacy of 5-fluorouracil by epigallocatechin-3- gallate co-loaded in wheat germ agglutinin-conjugated nanoparticles.
Topics: Animals; Apoptosis; Catechin; Colonic Neoplasms; Fluorouracil; HT29 Cells; Humans; Mice; Nanoconjuga | 2019 |
Impact of acetylsalicylic acid on tumor angiogenesis and lymphangiogenesis through inhibition of VEGF signaling in a murine sarcoma model.
Topics: Animals; Aspirin; Fluorouracil; Lymphangiogenesis; Lymphatic Vessels; Male; Mice; Neovascularization | 2013 |
Interplay between heme oxygenase-1 and miR-378 affects non-small cell lung carcinoma growth, vascularization, and metastasis.
Topics: Animals; Antineoplastic Agents; Carbon Monoxide; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; C | 2013 |
Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Cell Cycle; Colorectal Neopla | 2013 |
Visualising and quantifying angiogenesis in metastatic colorectal cancer : A comparison of methods and their predictive value for chemotherapy response.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cape | 2013 |
Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Hum | 2013 |
Corticotropin-releasing factor reduces tumor volume, halts further growth, and enhances the effect of chemotherapy in 4T1 mammary carcinoma in mice.
Topics: Animals; Apoptosis; Breast Neoplasms; Corticotropin-Releasing Hormone; Female; Fluorouracil; Humans; | 2014 |
Differential therapeutic effects of anti-VEGF-A antibody in different tumor models: implications for choosing appropriate tumor models for drug testing.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antineoplastic | 2014 |
Simvastatin sensitizes human gastric cancer xenograft in nude mice to capecitabine by suppressing nuclear factor-kappa B-regulated gene products.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Capecitabine; Cell Line, Tumor; Cell Proliferation; Deoxycyti | 2014 |
Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis Regulatory Proteins; Cell Cycle Proteins; Cell L | 2014 |
[Long-term survival of a patient with hepatocellular carcinoma with portal vein tumor thrombus treated with interferon-α and 5-fluorouracil combination therapy].
Topics: Antimetabolites, Antineoplastic; Antiviral Agents; Carcinoma, Hepatocellular; Chemoembolization, The | 2013 |
Antitumor effect of a selective COX-2 inhibitor, celecoxib, may be attributed to angiogenesis inhibition through modulating the PTEN/PI3K/Akt/HIF-1 pathway in an H₂₂ murine hepatocarcinoma model.
Topics: Animals; Antigens, CD34; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Celecoxib; Cell | 2014 |
Impending Carotid Blowout Syndrome.
Topics: Angiography; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Caro | 2015 |
Suppression of colorectal cancer liver metastasis by apolipoprotein(a) kringle V in a nude mouse model through the induction of apoptosis in tumor-associated endothelial cells.
Topics: Animals; Apolipoproteins A; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Endoplasmic Reticulum | 2014 |
Anti-angiogenesis participates in antitumor effects of metronomic capecitabine on colon cancer.
Topics: Administration, Metronomic; Animals; Antimetabolites, Antineoplastic; Capecitabine; Cell Cycle; Cell | 2014 |
Correlation of tumor-infiltrative lymphocyte subtypes alteration with neoangiogenesis before and after neoadjuvant chemotherapy treatment in breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Duct | 2014 |
Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Effect of standard chemotherapy and antiangiogenic therapy on plasma markers and endothelial cells in colorectal cancer.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera | 2014 |
Dopamine is a safe antiangiogenic drug which can also prevent 5-fluorouracil induced neutropenia.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Blood Pressure; Cell Line, Tumor; | 2015 |
The cholesterol biosynthesis enzyme oxidosqualene cyclase is a new target to impair tumour angiogenesis and metastasis dissemination.
Topics: Animals; Apoptosis; Benzophenones; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferatio | 2015 |
Anti-angiogenic effects of resveratrol in combination with 5-fluorouracil on B16 murine melanoma cells.
Topics: AMP-Activated Protein Kinases; Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; An | 2015 |
5-Fluoruracil blocked giant cell tumor progression by suppressing osteoclastogenesis through NF-kappaB signals and blocking angiogenesis.
Topics: Animals; Antimetabolites, Antineoplastic; Bone Resorption; Cell Differentiation; Cell Lineage; Chemo | 2015 |
Vascular-targeted TNFα improves tumor blood vessel function and enhances antitumor immunity and chemotherapy in colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Bone Marrow; Cell Line; Cell Line, Tumor; Cell-Penetrating | 2015 |
Differential interference of vitamin D analogs PRI-1906, PRI-2191, and PRI-2205 with the renewal of human colon cancer cells refractory to treatment with 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Calcitriol; Cell Self Renewal; Cell Survival; Colonic Neoplasms; Di | 2016 |
Effect of luteolin on gene expression in mouse H22 hepatoma cells.
Topics: Animals; Carcinoma, Hepatocellular; CD58 Antigens; Cell Line, Tumor; Cell Proliferation; Fluorouraci | 2015 |
Effect of Recepteur d'Origine Nantais expression on chemosensitivity and tumor cell behavior in colorectal cancer.
Topics: Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Humans; Lymphangiogenesis; Neovascu | 2016 |
Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Ce | 2016 |
Gold Nanoparticle-Mediated Targeted Delivery of Recombinant Human Endostatin Normalizes Tumour Vasculature and Improves Cancer Therapy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Models, | 2016 |
Changes in hepatic perfusion assessed by dynamic contrast enhanced MRI, associated with morphologic evaluation, in patients with liver metastases from colorectal cancer treated with first-line chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Colorectal Neo | 2016 |
Ursolic acid sensitized colon cancer cells to chemotherapy under hypoxia by inhibiting MDR1 through HIF-1α.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Cell Hypoxia; Cell | 2016 |
Gankyrin sustains PI3K/GSK-3β/β-catenin signal activation and promotes colorectal cancer aggressiveness and progression.
Topics: Animals; Antimetabolites, Antineoplastic; beta Catenin; Cell Movement; Cell Proliferation; Colorecta | 2016 |
Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2008 |
[Effect of Endostatin and SU6668 combined with 5-FU on human colon cancer xenograft in nude mice].
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Colonic Neoplasms; Endostatins; Fluorouracil; Hu | 2008 |
Molecular basis for the induction of an angiogenesis inhibitor, thrombospondin-1, by 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Base Sequence; Cell Line, Tumor; Chromatin Immunoprecipitation; Col | 2008 |
A novel assay to assess the effectiveness of antiangiogenic drugs in human breast cancer.
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplasti | 2008 |
Growth inhibitory effects of pegylated IFN-alpha2b and 5-fluorouracil in combination on renal cell carcinoma cell lines in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Transplantat | 2008 |
Antiangiogenic effect of capecitabine combined with ginsenoside Rg3 on breast cancer in mice.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Capecitabine; Cell Line, Tumor; D | 2008 |
Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Hypoxia; Doxorubicin; Fluorouracil; Humans; Image | 2008 |
Constitutive NF-kappaB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth.
Topics: Angiogenesis Inducing Agents; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma; Cell L | 2009 |
Antitumor effects of 2-oxoglutarate through inhibition of angiogenesis in a murine tumor model.
Topics: Angiogenesis Inhibitors; Animals; Blotting, Western; Carcinoma, Lewis Lung; Cell Proliferation; Enzy | 2009 |
Current role of bevacizumab in colorectal cancer.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2009 |
Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells.
Topics: Antigens, CD; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cadherins; Carcinoma, Hepatocellu | 2009 |
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell L | 2009 |
Vascular endothelial growth factor gene polymorphisms in patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2010 |
Effects of thymidine phosphorylase on tumor aggressiveness and 5-fluorouracil sensitivity in cholangiocarcinoma.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Bile Duct Neoplasms; Carcinoma, Squamous Cell; Cell Line | 2010 |
Pilot study to relate clinical outcome in pancreatic carcinoma and angiogenic plasma factors/circulating mature/progenitor endothelial cells: Preliminary results.
Topics: Aged; Angiopoietins; Antineoplastic Combined Chemotherapy Protocols; Chemokine CXCL12; Deoxycytidine | 2010 |
Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Proto | 2010 |
RGD modified albumin nanospheres for tumour vasculature targeting.
Topics: Animals; Antimetabolites, Antineoplastic; Cattle; Cells, Cultured; Drug Carriers; Drug Delivery Syst | 2011 |
Smad4 inactivation promotes malignancy and drug resistance of colon cancer.
Topics: Cell Hypoxia; Cell Movement; Cell Transformation, Neoplastic; Colonic Neoplasms; Drug Resistance, Ne | 2011 |
Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; | 2011 |
[A case of successful treatment by interferon-α and 5-fluorouracil combination therapy (FAIT) and transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality T | 2011 |
Soluble vascular endothelial growth factor decoy receptor FP3 exerts potent antiangiogenic effects.
Topics: Animals; Aorta; Cell Line, Tumor; Cell Proliferation; Female; Fluorouracil; Human Umbilical Vein End | 2012 |
First evidence that γ-tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capecitabine in a xenograft mouse model through the modulation of NF-κB pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Capecitabine; Cel | 2012 |
The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort | 2012 |
Design, synthesis, and activity evaluation of a new 5-fluorouracil prodrug containing an Asn-Gly-Arg(NO2)COOCH3 tripeptide.
Topics: Animals; Antimetabolites, Antineoplastic; CD13 Antigens; Cell Movement; Cells, Cultured; Collagen; D | 2012 |
Angiogenesis inhibition and cell cycle arrest induced by treatment with Pseudolarix acid B alone or combined with 5-fluorouracil.
Topics: Angiogenesis Inhibitors; Animals; Cell Cycle Checkpoints; Cell Movement; Diterpenes; Fluorouracil; H | 2012 |
Antitumor effects of FP3 in combination with capecitabine on PDTT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Capecitabine; Carcinoma | 2012 |
Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factor-targeting agents.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2012 |
Astrocyte elevated gene-1 promotes hepatocarcinogenesis: novel insights from a mouse model.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Adhesion Molecules; Cell Transformat | 2012 |
Targeting angiogenesis in metastatic breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2012 |
Breast cancer: assessing response to neoadjuvant chemotherapy by using US-guided near-infrared tomography.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal, Humanized; Antineoplastic Combin | 2013 |
Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Capecitabine; Celecoxib; Colorectal Neoplasms; | 2002 |
Study on the changes in microvessel density in hepatocellular carcinoma following transcatheter arterial chemoembolization.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, | 2001 |
Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2002 |
Validation of the role of angiogenesis as a chemotherapeutic target.
Topics: Adaptation, Physiological; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, | 2003 |
[Dynamic magnetic resonance tomography (dMRT). It's value in advanced head-neck tumors treated with radiochemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Contrast Media; Disease-Fr | 2003 |
Enhanced radiosensitization and chemosensitization in NF-kappaB-suppressed human oral cancer cells via the inhibition of gamma-irradiation- and 5-FU-induced production of IL-6 and IL-8.
Topics: Animals; Annexin A5; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Carcinoma; Cell | 2004 |
Blockage of 2-deoxy-D-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Aorta, Thoracic; Colonic Neoplasms; Deoxyr | 2004 |
Changes of tumor microcirculation after transcatheter arterial chemoembolization: first pass perfusion MR imaging and Chinese ink casting in a rabbit model.
Topics: Animals; Carbon; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Contrast Media; Diagnost | 2004 |
Comparison between triple therapy with octreotide, galanin and serotonin, 5-fluorouracil/leucovorin, and sequential treatment with both, on human colon cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; C | 2004 |
Embryonic endothelial progenitor cells armed with a suicide gene target hypoxic lung metastases after intravenous delivery.
Topics: Animals; Bone Neoplasms; Bystander Effect; Carcinoma, Lewis Lung; Cell Hypoxia; Cytosine Deaminase; | 2004 |
Bevacizumab targeted therapy: validation of angiogenesis as a key target for advanced colorectal cancer.
Topics: Androgen Antagonists; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb | 2004 |
Liposomes modified with cyclic RGD peptide for tumor targeting.
Topics: Animals; Cells, Cultured; Fluorouracil; Humans; Liposomes; Male; Mice; Mice, Inbred BALB C; Neoplasm | 2004 |
Importance of thymidine phosphorylase expression in tumor stroma as a prognostic factor in patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Carcinoma; | 2005 |
Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Cell Line, | 2005 |
Suppression of tumor growth by oncolytic adenovirus-mediated delivery of an antiangiogenic gene, soluble Flt-1.
Topics: Adenoviridae; Adenovirus E1B Proteins; Animals; Antimetabolites, Antineoplastic; Apoptosis; Colonic | 2005 |
Anti-tumour effects of triple therapy with octreotide, galanin and serotonin in comparison with those of 5-fluorouracil/leukovorin on human colon cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Body Weight; Cell Line, Tumor; C | 2005 |
Comparison between triple therapy with octreotide, galanin and serotonin vs. irinotecan or oxaliplatin in combination with 5-fluorouracil/leukovorin in human colon cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Body Weight; Camptothecin; Cell | 2005 |
Recombinant human erythropoietin alpha targets intratumoral blood vessels, improving chemotherapy in human xenograft models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2005 |
Albumin-bound nanoparticle paclitaxel.
Topics: Albumin-Bound Paclitaxel; Albumins; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; | 2005 |
Anti-angiogenic therapy and chemotherapy affect 99mTc sestamibi and 99mTc-HL91 accumulation differently in tumour xenografts.
Topics: 2-Methoxyestradiol; Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Estradiol; Fluorouracil; Hum | 2005 |
Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor malignancies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop | 2006 |
Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2006 |
Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2006 |
Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2006 |
Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2006 |
[Effects of norcantharidin on angiogenesis of human gallbladder carcinoma and its anti-angiogenic mechanisms].
Topics: Angiostatins; Animals; Antimetabolites, Antineoplastic; Apoptosis; Bridged Bicyclo Compounds, Hetero | 2006 |
Antiproliferative effects of 5-fluorouracil and interferon-alpha in combination on a hepatocellular carcinoma cell line in vitro and in vivo.
Topics: Angiogenic Proteins; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; | 2006 |
Carbogen breathing differentially enhances blood plasma volume and 5-fluorouracil uptake in two murine colon tumor models with a distinct vascular structure.
Topics: Animals; Antimetabolites, Antineoplastic; Carbon Dioxide; Cell Line, Tumor; Colonic Neoplasms; Disea | 2006 |
[Effect of angiogenesis inhibitor SU6668 on the growth and metastasis of gastric cancer in SCID mice].
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Line, Tumor; Drug Synergism; Fluorouracil; Humans; | 2006 |
[Effect of vascular endothelial growth factor antibody Avastin on angiogenesis of human gastric cancer growing orthotopically in nude mice].
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimet | 2006 |
High-dose, short-term, anti-inflammatory treatment with dexamethasone reduces growth and augments the effects of 5-fluorouracil on dimethyl-alpha-benzanthracene-induced mammary tumors in rats.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anti-Inflammatory Agents; Carcinogens; Dexamethasone; Dru | 2006 |
Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2006 |
Hypoxia-induced cytosine deaminase gene expression for cancer therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Lewis Lung; Cell Line, Tumor; Cytosine Deaminas | 2007 |
Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities.
Topics: Angiogenesis Inhibitors; Angiotensin-Converting Enzyme Inhibitors; Animals; Antineoplastic Combined | 2007 |
Synergistic antitumor effects of celecoxib with 5-fluorouracil depend on IFN-gamma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colonic Neoplasms; Cyclooxygenas | 2007 |
Angiogenic effect of naive and 5-fluorouracil resistant colon carcinoma on endothelial cells in vitro.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Coculture Techniques; Colonic Neoplasms; Dru | 2007 |
Bevacizumab plus 5-fluorouracil induce growth suppression in the CWR-22 and CWR-22R prostate cancer xenografts.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis | 2007 |
Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins.
Topics: Angiopoietins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepato | 2007 |
[Study of the anti-tumor effect of anti-vascular endothelial growth factor McAb 5-fluorouracil loaded polylactic acid nanoparticles].
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Cell Line, Tumor; Drug Carriers; F | 2007 |
Daily low-dose/continuous capecitabine combined with neo-adjuvant irradiation reduces VEGF and PDGF-BB levels in rectal carcinoma patients.
Topics: Antimetabolites, Antineoplastic; Becaplermin; Capecitabine; Carcinoma; Combined Modality Therapy; De | 2008 |
Interferon-alpha in combination with chemotherapy has potent antiangiogenic properties in an orthotopic mouse model for pancreatic adenocarcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Cel | 2008 |
Fluorouracil for the treatment of massive periretinal proliferation.
Topics: Animals; Cells, Cultured; Fibroblasts; Fluorouracil; Neovascularization, Pathologic; Rabbits; Retina | 1982 |
5-fluorouracil and glaucoma filtering surgery. II. A pilot study.
Topics: Adolescent; Adult; Aged; Cataract Extraction; Child; Cicatrix; Combined Modality Therapy; Dose-Respo | 1984 |
Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470) and cytotoxic agents in mice.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Body Weight; C | 1994 |
Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 1993 |
Changes in tumor vascular permeability in response to experimental radioimmunotherapy: a comparative study of 11 xenografts.
Topics: Animals; Antibodies, Bispecific; Antidotes; Antimetabolites, Antineoplastic; Capillary Permeability; | 1997 |
Angiogenesis and stromal fibronectin expression in invasive breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 1998 |
Expression of platelet-derived endothelial cell growth factor in oral and oropharyngeal carcinoma.
Topics: Analysis of Variance; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Female; Fluorouraci | 1998 |
Angiogenesis vs. response after combined chemoradiotherapy of squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1999 |
UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice.
Topics: 4-Butyrolactone; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cel | 1999 |
Inhibition of angiogenesis and intrahepatic growth of colon cancer by TAC-101.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Be | 1999 |
The expression of thymidine phosphorylase correlates with angiogenesis and the efficacy of chemotherapy using fluorouracil derivatives in advanced gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom | 1999 |
Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Co | 2000 |
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cornea; Cyclophosphamide; Drug Administration Schedule; D | 2000 |
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cornea; Cyclophosphamide; Drug Administration Schedule; D | 2000 |
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cornea; Cyclophosphamide; Drug Administration Schedule; D | 2000 |
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cornea; Cyclophosphamide; Drug Administration Schedule; D | 2000 |
An experimental model of tumor dormancy therapy for advanced head and neck carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antioxidan | 2000 |
Angiogenesis sustains tumor dormancy in patients with breast cancer treated with adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 2001 |
Impact of thymidine phosphorylase surexpression on fluoropyrimidine activity and on tumour angiogenesis.
Topics: Animals; Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Resistance, Neoplasm; Floxuridine; | 2001 |
Biopsy specimen microvessel density is a useful prognostic marker in patients with T(2-4)M(0) esophageal cancer treated with chemoradiotherapy.
Topics: Adult; Aged; Biomarkers, Tumor; Cisplatin; Combined Modality Therapy; Cyclin D1; Dihydrouracil Dehyd | 2002 |
Prognostic value of thymidine phosphorylase expression in breast carcinoma.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2002 |
Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, an inhibitor of angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Aorta; Breast Neoplasms; Cell Movement; Cou | 2002 |
gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma; Carc | 2001 |
Basic fibroblast growth factor infusion increases tumour vascularity, blood flow and chemotherapy uptake.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Blood Flow Velocity; Fibroblast Growth Fac | 2002 |
Inhibitory effects of anti-angiogenic agents on neovascularization and growth of the chorioallantoic membrane (CAM). The possibility of a new CAM assay for angiogenesis inhibition.
Topics: Allantois; Animals; Chick Embryo; Chorion; Cortisone; Drug Evaluation, Preclinical; Extraembryonic M | 1986 |
5-Fluorouracil and glaucoma filtering surgery. III. Intermediate follow-up of a pilot study.
Topics: Aphakia; Conjunctiva; Eye; Fluorouracil; Follow-Up Studies; Glaucoma; Humans; Injections; Neovascula | 1986 |
Adjusting the dose of 5-fluorouracil after filtration surgery to minimize side effects.
Topics: Adult; Aged; Female; Fluorouracil; Glaucoma; Humans; Inflammation; Intraocular Pressure; Iris; Male; | 1987 |
[Treatment of neovascular glaucoma by seton and 5-FU].
Topics: Combined Modality Therapy; Diabetes Complications; Fluorouracil; Glaucoma; Humans; Male; Methods; Mi | 1987 |